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ABSTRACT 
JIN LI: Genetic association studies: application in the investigation of biomarkers related to 
cardiovascular diseases and study design 
(Under the direction of Ethan M. Lange) 
 
             Cardiovascular disease (CVD) is the No. 1 cause of death in the United States, killing 
about 610,000 people every year. Biomarkers are important tools to identify vulnerable 
individuals at high risk of CVD. Investigation of the genetic architecture for biomarkers and 
other risk factors related to CVD is of critical importance in the prevention and treatment of 
CVD. 
            For my first chapter, I conducted genome-wide admixture and association studies for 
iron-related traits in 2347 African Americans (AAs) participants from the Jackson Heart Study 
(JHS). I identified, for the first time, a second independent genome-wide significant signal in the 
TF region associated with total iron binding capacity levels. I also identified a novel functional 
missense variant in the G6PD-GAB3 region significantly associated with ferritin levels. Both 
results were replicated in a second AA cohort with iron measures. 
           For my second chapter, I conducted genome-wide admixture and association studies, and 
gene-based exome-wide association studies of rare variants, to identify variants or genes, 
harboring a high burden of rare functional variants, associated with lipoprotein(a) [Lp(a)] 
cholesterol levels in 2895 AAs participating in the JHS. I observed significant evidence for 
association between Lp(a) and both local ancestry and hundreds variants spanning ~10Mb the 
iv 
 
LPA gene region on chromosome 6q. Of note, the region containing associated variants became 
much narrower, centered over the LPA gene (<1Mb), after adjusting for local ancestry. I also 
observed a single significant non-synonymous SNP in APOE and a high burden of coding 
variants in LPA and APOE significantly associated with Lp(a) levels 
            For my third chapter, I investigated the genetic association of four candidate variants with 
blood pressure and tested the modifying effects of environmental factors in 7,319 Chinese adults 
from the China Nutrition and Health Survey (CHNS). I observed that rs1458038 exhibited a 
significant genotype-by-BMI interaction affecting blood pressure measures, with the strongest 
variant effects in those with the highest BMI. 
           Finally, for my last chapter, I described a multistage GWAS study design that uses 
selective phenotyping to increase power for studies with existing genome-wide genotypic data 
and to-be-measured quantitative phenotypes that are under a sample-size constraint. The 
approach uses simulated annealing to identify the optimal subset of subjects to be phenotyped in 
Stage 2 of a two-stage GWAS. I showed that our approach has greater statistical power than the 
conventional approach of randomly selecting a subset of subjects for phenotyping. We 
demonstrate the gains in power for both directly genotyped and imputed genetic variants. 
          Together, these studies further our understanding of the genetic architecture of risk factors 
for CVD, suggest some candidates for future genetic and molecular studies, and also shed some 
light on the study design of future large-scale genetic association studies where the cost 
constraints will be determined by the expense of measuring new biomarkers in studies that have 
existing genetic data. 
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CHAPTER I: INTRODUCTION 
 
Cardiovascular diseases 
               Cardiovascular disease (CVD) is the No. 1 cause of death in the United States, 
killing about 610,000 people every year (1). It is the leading cause of death for both 
American men and women, and for people of most ethnicities in the United States, including 
African Americans, Hispanics, and whites. The 2011 overall rate of death attributable to 
CVD was 229.6 per 100 000 Americans, 275.7 for males and 192.3 for females, 271.9 for 
white males, 352.4 for black males, 188.1 for white females, and 248.6 for black females (2). 
CVD claims more lives than all forms of cancer combined. On the basis of 2011 death rate 
data, approximately 155 000 Americans who died of CVD in 2011 were <65 years of age, 
and 34% of deaths attributable to CVD occurred before the age of 75 years, which is younger 
than the current average life expectancy of 78.7 years. Worldwide, the Global Burden of 
Disease study estimated that in 2001, 12.45 million of >56 million total worldwide deaths 
were caused by CVD, and the number of deaths caused by CVD increased to 17 million in 
2008 (3, 4). High blood pressure, high LDL cholesterol, and smoking are key risk factors for 
heart disease. Several other important risk factors include diabetes, obesity, poor diet, high 
stress, physical inactivity, and excessive alcohol use (5). Despite these environmental factors, 
genetic factors are also significant contributors to CVD. The familial clustering of CVD and 
its heritability are well established, with the heritability of CVD estimated at about 40% (6).  
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Biomarkers 
            Biomarkers are defined as measurable and quantifiable biological parameters that are 
objectively measured and evaluated as indicators for disease trait (risk factor or risk marker), 
disease state (preclinical or clinical), or disease rate (progression) (7). Biomarkers are important 
tools to identify vulnerable individuals at high risk of CVD, and to diagnose disease conditions 
promptly and accurately. Traditional risk factors (cigarette smoking, diabetes, hyperlipidaemia 
and hypertension) are observed in only a subset of individuals who develop CVD. Up to 20% of 
patients have no traditional risk factors, and 40% have only one (8). Thus, identifying novel risk 
markers for CVD has significant potential to improve the selection of individuals for 
preventative strategies. Furthermore, biomarkers are typically more proximal to gene products 
than disease outcomes, and thus, they can serve as a surrogate for end points of CVD and help 
better understand the genetic contribution to CVD (9). Classical CVD biomarkers included lipid 
profiles, inflammation factors, coagulation factors, cytokines, etc (7). In this dissertation, 
biomarkers that were specifically investigated included iron-related measures and lipoprotein(a).  
 
Iron-related measures 
    Iron is critical to an array of metabolic functions, such as oxygen transport and oxidative 
phosphorylation. Normally, small daily losses of iron in the feces and through menstruation are 
balanced by its regulated intestinal absorption and its recovery from heme after phagocytosis of 
senescent red blood cells (10). Controversies have existed for some time regarding the 
association between iron status and CVD. A recent review suggested that in the reference range, 
iron status has a neutral effect, while extreme conditions of iron deficiency, as well as of iron 
overload, are associated with modestly increased CVD risk, although with different proposed 
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mechanisms (11). A study showed that trivalent iron (FeIII) initiates a hydroxyl radical-catalyzed 
conversion of fibrinogen into a fibrin-like polymer (parafibrin) that is remarkably resistant to the 
proteolytic dissolution and thus promotes its intravascular deposition (12). Another possible 
mechanism underlying the association between iron overload and CVD is that of oxidative stress 
(13). Ferrous iron catalyzes a variety of free-radical oxidative reactions which generate reactive 
oxygen species (ROS). ROS may seriously damage cellular integrity and contribute directly to 
plaque disruption and thrombosis. A study on a Finnish cohort showed that serum ferritin was 
associated with most of the measured oxysterols, independently of major confounders, and also 
associated with an increased risk of myocardial infarction, independent of major cardiovascular 
risk factors (14, 15). On the other hand, iron deficiency can also lead to increased CVD risk. 
Since iron can inhibit thrombopoiesis, iron deficiency can lead to thrombocytosis due to lack of 
inhibition of thrombopoiesis (16). In addition, iron deficiency can cause anemia.  Anemia 
increases work load of the heart due to increased heart rate and stroke volume, and this may 
cause ischemia, myocardial cell death and heart failure (17). 
  Laboratory tests typically used to assess iron transport and storage include serum iron, total 
iron binding capacity (TIBC), transferrin saturation (SAT), and serum ferritin. Genetic factors 
could affect iron metabolism through gastrointestinal absorption, transport, tissue uptake, storage, 
or remobilization from tissue stores, and thus could have a large impact on the variation of these 
iron-related measures (18, 19). Previous genetic analyses of iron metabolism have identified 
several variants associated with markers of iron status, including HFE variants with serum 
ferritin, transferrin, and SAT (20), TF variants with serum ferritin levels (20), TMPRSS6 variants 
with hemoglobin, serum iron and SAT (21, 22), PCSK7 variants with soluble transferrin receptor 
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(23), TFR2 variants with hemochromatosis type 3 (24), and a locus on chromosome 2p14, tagged 
by SNP rs2698530, with iron deficiency (25).  
 
Lipoprotein(a) 
          Lipoprotein (a) [Lp(a)]  is a low-density lipoprotein (LDL)-like particle that consists of 
an apolipoprotein(a) covalently linked to apolipoprotein B100 by a disulfide bond (26).  Lp(a) is 
an independent risk factor for CVD (27, 28). The association of elevated Lp(a) and coronary 
heart disease (CHD) has been reviewed recently in a 2009 meta-analysis (20). In the 24 cohort 
studies, the risk ratio for CHD was 1.13 (95% CI 1.09-1.18) after adjustment for lipids and other 
conventional risk factors. Lp(a) excess is observed in 18.6% patients with premature CHD 
(includes 12.7% with no other dyslipidemias) (29). Elevated Lp(a) predicts 15-year CVD 
outcomes and improves CVD risk prediction, and the hazard ratio for incident CVD was 1.37 per 
1-SD higher Lp(a) level (30). Lp(a) is believed to both promote atherosclerosis and enhance 
thrombosis by multiple mechanisms. Like other lipoproteins, Lp(a) is bound by VLDL receptors 
in atherosclerotic macrophage and is detected in larger amounts in tissue from culprit lesions  in 
patients with unstable coronary artery disease (31). More importantly, Lp(a) plays a role in 
enhancing thrombotic events through its anti-fibrolytic activity. The final vascular obstruction 
that occurs in atherosclerosis in myocardial infarction and stroke is due to sudden thrombosis at 
the sight of a narrowed artery. Since Lp(a) contains a region (Kringle IV) that mimics 
plasminogen, it has been proposed to prevent the inhibition of clot lysis (32), leading to an 
increased susceptibility to CVD. Other studies have found that Lp(a) may enhance 
atherosclerosis by the formation of circulating immune complexes with IgG antibodies specific 
for Chlamydia pneumonia (33), although the specific mechanisms of this have not been reported. 
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        Genetic factors have a large impact on the variation of Lp(a) levels and approximately 
70-90% of the total variance of Lp(a) can be attributed to variation within the LPA locus across 
worldwide populations(34, 35). Genetic variants in LPA gene are strongly associated with both 
an increased level of Lp(a) and an increased risk of coronary disease(36). In the LPA locus, a 
copy-number variation (CNV) which encodes a Kringle(IV) type 2 domain accounts for 
approximately half of variance explained by LPA locus(37, 38). Recent genome-wide association 
studies (GWAS) in subjects of European descent have identified multiple polymorphisms 
spanning 12.5 Mb on chromosome 6q26-27, which includes LPA, that are significantly 
associated with Lp(a) levels independent of each other and of the Kringle IV size polymorphism 
in LPA (p<5x10
-8
) (37).  A candidate gene study on multi-ethnic populations suggested both 
SNPs at 6q26-27 and the Kringle IV CNV were genomic determinants of Lp(a) level, and the  
proportion of total variance explained by each determinant differ across ethnic groups (39). 
 
Hypertension 
Hypertension is a conventional and important risk factor for CVD (40). Globally, 
complications of hypertension are responsible for 9.4 million deaths every year (41). 
Hypertension is responsible for at least 45% of deaths due to heart disease, and 51% of deaths 
due to stroke. In 2008, worldwide, approximately 40% of adults aged 25 and above had been 
diagnosed with hypertension; the number of people with the condition rose from 600 million in 
1980 to 1 billion in 2008 (42). Overall, low- and middle- income countries have a higher 
prevalence and larger number of hypertension patients who are undiagnosed, untreated and have 
their blood pressure uncontrolled compared to high-income countries (42). Hypertension 
adversely impacts heart and blood vessels in various ways (43, 44). An increased pressure in 
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blood vessels will cause the heart to work harder in order to pump blood, thus, hypertension can 
lead to a heart attack, an enlargement of the heart and heart failure (43). A consistent high blood 
pressure will result in weak spots on the blood vessels, making them more vulnerable to clog and 
burst, which leads to strokes when blood leaks out into the brain (45).  
It is well established that hypertension is determined by both genetic factors and 
environmental factors, including tobacco use, salt and alcohol intake, body mass index (BMI), 
and physical activity, and their complex interactions (46) (47). Blood pressure has long been 
established as an inheritable trait (48), and an estimated 30-60% of blood pressure variation is 
explained by genetic factors (49). Longitudinal data of Framingham Heart Study suggested that 
57% and 56% of inter-individual variability in systolic (SBP) and diastolic blood pressure (DBP), 
respectively, were due to genetic factors (50) in Caucasians. Data from Nigerian families suggest 
heritabilities of 40% and 36% for SBP and DBP in Africans (51), and data from the Chinese 
population suggest heritabilities of 31% and 32% for SBP and DBP, respectively, in Asians (52). 
Through GWAS meta-analyses in recent years, numerous loci have now been identified to be 
associated with blood pressure variation in different populations.   
 
Genetic association studies 
           It is well established that genetic variation, including single nucleotide polymorphisms 
(SNPs), insertion/deletion polymorphisms, variable number tandem repeats, microsatellites, etc, 
could lead to important biological changes in protein production and/or structure, which provides 
biochemical basis for much of the diversity in the physiological characteristics of individuals, 
and also susceptibilities to various diseases and other disorders. Genetic association studies aim 
to compare the frequencies of the alleles or genotypes at each genomic site of interest between 
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populations of cases and controls to determine whether genotype at the site is associated with 
susceptibility to certain diseases. A higher frequency of the less-common variant allele in cases 
is taken as evidence that the allele or genotype is associated with increased risk of disease (53). 
For quantitative traits, we assess whether genotype is associated with higher/lower levels of the 
trait in a cohort of individuals. Genetic association studies include many different study designs 
ranging from family studies to studies on tens of thousands of unrelated participants. Studies of 
quantitative traits can include either randomly selected individuals or highly selected individuals 
selected for having extreme phenotype values. 
 
Candidate gene association studies 
             Candidate gene association studies have been a powerful approach to discover genetic 
variants associated with complex traits.  Candidate gene studies are relatively cheap and quick to 
perform, and are focused on the selection of genes that, presumably, have some relevance in the 
mechanism of the disease being investigated. The selection of candidate genes often comes from 
prior knowledge about gene function (54). To date, candidate genes have been conﬁrmed for 
many different diseases and traits (55). However, many published candidate gene association 
studies have been limited by small sample sizes, reducing statistical power, and inadequate 
correction for multiple testing, where the multiple test correction for a study only reflects the 
number of variants tested in the reported gene and not all variants tested across all previous 
genes considered but not reported. Thus, historically, few candidate gene studies have achieved 
robust results that could be replicated by other investigators. Despite its decreasing popularity, 
candidate gene studies are still being used as a complementary approach for GWAS, particularly 
for replication analyses. Further, because GWAS commercial arrays have often been agnostic 
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with respect to variant function when selecting variants for inclusion and preference is given to 
linkage disequilibrium tagging variants, the coverage of biologically functional variants is often 
poor in GWAS studies. The poor coverage of functional variants on many GWAS panels has led 
to the development of gene-centric arrays that facilitate the investigation of a large number of 
variants, including uncommon functional variants, in genes involved in relevant biological 
pathways (56, 57), As a result, recent candidate gene association studies have achieved success 
in identifying genetic associations that are often replicated in independent samples. One 
successful example is the identification of blood pressure-related SNPs using the HumanCVD 
BeadChip, which includes approximately 50,000 SNPs from 2000 genes known to be associated 
with CVD-related traits, based on a discovery-stage sample of 25118 subjects and a replication-
stage sample of 59349 subjects (57). 
Genome-wide association studies  
            With the emergence of high-throughput genotyping techniques, array-based GWAS has 
become a widely used approach to identify genetic variants associated with common complex 
diseases. GWAS is a comprehensive discovery-driven approach to systematically test SNPs 
across the genome for association with dichotomous or continuous traits. By taking advantage of 
linkage disequilibrium (LD) and genotype imputation technology to capture most of genome’s 
variation, a group of tag SNPs can be genotyped and used to evaluate the majority of genome-
wide common genetic variation. Since the first GWAS reported in 2005 (58), more than 1500 
GWAS have been conducted leading to the successful identification of susceptibility loci for a 
wide range of human complex diseases.  In order to increase statistical power to detect some 
associations with variants having modest effects, consortia, with the purpose of conducting 
GWAS meta-analyses in very large samples, have been formed (59). Despite the huge success it 
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has achieved, GWAS still has some limitations. Since GWAS evaluates a large number of 
individual SNPs (>10
6
), the threshold of statistical significance is usually set to be very stringent 
(P<5x10
-8
) in order to avoid false-positive associations, thus some variants with modest effects 
are not easy to be detected unless large-scale GWAS meta-analyses are conducted. More 
importantly, the majority of loci identified by GWAS are in the intergenic or intronic region of 
the genome, and the function of these variants are largely unknown. Post hoc investigations need 
to be conducted in order to learn whether these variants of unknown function have effects on 
mRNA expression or any other physiological activities on a molecular, cellular, or systematic 
level.  Although a large number of variants were identified by GWAS, they collectively explain a 
limited proportion of the total variation of most of the traits being studied, leaving a large 
proportion of heritability unexplained. Therefore, new approaches are being developed to help 
explain the missing heritability.   
 
Exome sequencing and Exome Beadchip 
          It has been hypothesized that much of the missing heritability that GWAS fails to explain 
may reside in low-frequency or rare variants (60). The successful identification of rare variants 
that have a large influence on lipid traits, found by sequencing extremes of the population 
distribution, is one example of the large role that rare variants can play on complex diseases (61). 
While early sequencing studies typically only sequenced a limited number of genes, the 
emergence of next-generation sequencing (NGS) technology has now enabled investigators to 
deeply sequence large stretches of DNA, whole exomes, and even entire genomes in large 
population-based studies (62). The National Heart, Lung, and Blood Institute launched a whole-
exome sequencing project based on >6500 individuals to identify low-frequency and rare 
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variants associated with heart, lung, and blood disorders (63). Exome sequencing has led to the 
discovery of thousands of rare functional variants that have now been included on genotyping 
arrays such as the Illumina HumanExome BeadChip. The Illumina HumanExome BeadChip is a 
genotyping array containing 247,870 variants discovered through exome sequencing in ~12,000 
individuals, with ~75% of the variants with a MAF<0.5%. The main content of the chip 
comprises protein-altering variants (nonsynonymous coding, splice-site and stop gain or loss 
codons) seen at least three times in a single study and in at least two studies (64). So far, it has 
enabled identification of several rare functional variants associated with fasting glucose, insulin 
processing, and type 2 diabetes susceptibility (65) (66). 
 
Gene-gene and Gene-environment interactions 
             It is widely believed that human complex traits are influenced by the interaction between 
genetic and environmental (G-E) factors. It is also widely held that such interactions will help 
explain some of the missing heritability of GWAS and provide better insight into pathway 
mechanisms for complex diseases (67). Quantifying G-E interactions may help develop 
improved predictive models, either for disease onset or for response to treatment. Improved 
predictive models of disease risk can enable preventive strategies, particularly when the risk 
factors include modifiable environmental exposures, and can advance individualized medicine 
by assessing a patient’s chance of responding to a particular treatment regimen (68). To date, 
most interaction studies are conducted after main effects have been identified, as current methods 
for detecting interactions on a genome-wide scale suffer from a lack of power due to the high 
cost of multiple test correction (69). However, scanning for the main effects might miss 
important genetic variants specific to subgroups of the population. In fact, interactions with 
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opposite effects in 2 different exposure groups (cross-interactions) will not show a main effect 
and will, therefore, not be identified using standard approaches (67). Therefore, there is a need 
for the further development of methods to identify gene-environment interactions in the context 
of genome-wide association studies. 
 
Genetic admixture mapping 
          While early GWAS were performed mostly on Caucasians, nowadays more and more 
GWAS studies are being conducted in other populations, including admixed populations. The 
fact that many of the significant variants discovered in Caucasians are also found to reach 
genome-wide significance in other populations suggests that the physiologic effects of many 
common variants may be generalized across populations with diverse genetic backgrounds (70). 
Admixed populations are populations that have variable levels of inherited ancestry from more 
than one ancestral population. Publically available genotype data (e.g. from HapMap) from 
contributing parental ancestral populations to the admixed population allows us to 
probabilistically infer the ancestral origin of alleles in a given individual at a given marker 
location. For example, for AAs, with available genetic data we can accurately infer at any given 
location the probability that the participant inherited 0, 1 or 2 copies of an African derived 
chromosome using HapMap CEU (Northern European) and YRI (Nigerian) haplotype data. 
Genetic admixture mapping is an approach to investigate whether genomic factors specific to 
one contributing ancestral population disproportionately influences certain traits in admixed 
population (71, 72). Since traditional admixture mapping has typically a substantially lower 
mapping resolution than association analysis (73), due to the often long stretches of ancestral 
haplotypes kept intact from the relatively recent admixture events, and the increasing availability 
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of high-density genetic data that includes variants specific to one ancestral population or another, 
the analysis of admixed populations is now moving from admixture mapping towards SNP 
association.  
          In admixed populations, population stratification (the confounding between background 
ancestry and individual variant allele frequencies on traits with ancestry-variable prevalence) can 
lead to false associations. In order to control for this population stratification, several methods 
have been developed in the past decade, including genomic control (74), structured association 
(75), and principal components-based methods (76). The general idea of these methods is to use 
markers across the genome to capture the global population structure within the study subjects. 
These methods may be ineffective in removing the effect of population stratification if it is 
induced by natural selection that occurs only at certain genomic regions. Thus, for admixed 
populations, controlling for local ancestry, in addition to global ancestry, provides an additional 
layer of protection from reporting false associations.  
 
Multistage association studies 
            Historically, the cost of genotyping 100 000’s of variants using commercial genotyping 
arrays has limited the available sample sizes for GWAS studies.  To remedy these costs, 
multistage GWAS studies were often utilized, where a subset of participants were included on 
the GWAS commercial array (Stage 1) and the remaining samples were genotyped on 
considerably smaller, and cheaper, arrays (Stage 2) containing a subset of variants demonstrating 
evidence for association in Stage 1. Data from both stages are combined for the overlapping set 
of variants to assess the overall significance of any discoveries.  It has been shown, under careful 
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design, that the two-stage study has similar statistical power to conventional single-stage studies 
but at a fraction of the cost.  
  As of today, hundreds of thousands of subjects with available GWAS data exist and 
much of the focus is now on measuring and analyzing novel biomarkers in cohorts with these 
existing GWAS data. As a result, the burden of expense is now shifting from the cost of 
genotyping to the cost of additional phenotyping, especially when phenotyping involves mRNA 
abundance data obtained from microarray or RNA-seq experiments, novel blood-based 
biomarkers or complex physiological and behavioral trait scale variables. Often it is not feasible, 
due to cost constraints, to phenotype all subjects with available genetic data. Selective 
phenotyping is a way of capturing the beneﬁts of large population sizes without the need to carry 
out large-scale phenotyping (77). It utilizes available genetic information to select subsets of 
individuals to be phenotyped in a manner to increase overall power for the study. Methods to 
maximize power using selective phenotyping have been developed for a long time (78-81). The 
common rationale behind these methods is to identify the subset of subjects who are as 
genetically dissimilar as possible with respect to distributions of the genotype data for the 
specific markers of interest.  
         Selective phenotyping designs in genetic studies have been proposed for one-stage genetic 
association studies where there is an established set of variants of interest for study. 
Unfortunately, for most novel traits the identity of the “interesting” variants is unknown. GWAS 
studies are largely discovery-based studies. A reasonable approach to increase statistical power 
under fixed cost constraints is to randomly phenotype a subset of subjects and test across all 
variants (Stage 1) in order to identify a subset of “interesting” variants that can be targeted for 
selective phenotyping (Stage 2) in the remaining participants with genetic data. The results from 
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Stages 1 and 2 are then combined to assess significance of all variants (genotyped or imputed), 
where power has been enriched, by using selective phenotyping, for the subset of variants 
demonstrating strong evidence for association in Stage 1.     
           This dissertation consists of four chapters. The first two chapters aimed to identify the 
genetic variants associated with levels of iron-related measures and Lp(a) in a population of 
African Americans (AAs)  from JHS using genome-wide admixture mapping, GWAS, and rare-
coding-variant analyses using Exome Beadchip data. The third chapter aimed to assess the 
interaction between genetic factors and BMI on affecting blood pressure levels in a population- 
and household-based cohort study from China using a targeted candidate gene association study. 
The fourth chapter aimed to describe a two-stage GWAS using selective phenotyping for cohorts 
with existing genetic data who are subject to budgetary constraints when measuring new traits of 
interest.  
.  
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CHAPTER II: GENOME-WIDE ADMIXUTRE AND ASSOCIATION STUDY OF 
SERUM IRON, FERRITIN, TRANSFERRIN SATURATION, AND TOTAL IRON 
BINDING CAPACITY IN AFRICAN AMERICANS 
1
 
 
Introduction 
Iron is critical to an array of metabolic functions, such as oxygen transport and oxidative 
phosphorylation. Normally, small daily losses of iron in the feces and through menstruation are 
balanced by its regulated intestinal absorption and its recovery from heme after phagocytosis of 
senescent red blood cells (10). Iron deficiency can cause anemia, while iron overload may lead to 
increased risk for cardiovascular disease including cardiomyopathy, diabetes mellitus, arthritis, 
and liver disease (18). Laboratory tests typically used to assess iron transport and storage 
included serum iron, total iron binding capacity (TIBC), transferrin saturation (SAT), and serum 
ferritin. Ferritin, the predominant iron storage protein, reflects the cumulative iron stores in the 
bone marrow and tissues. Transferrin functions in iron transport, and the concentration of 
transferrin is proportional to the total iron binding capacity (TIBC) in serum. Transferrin 
saturation (SAT), calculated as (serum iron/TIBC) × 100, is affected by the rate of iron 
absorption in the small bowel as well as the sufficiency of tissue iron stores. Genetic factors 
could affect iron metabolism through gastrointestinal absorption, transport, tissue uptake, storage, 
or remobilization from tissue stores, and thus could have a large impact on the variation of these 
iron-related measures (18, 19).  
                                                 
1
 A version of this work was previously published as Li J et al. Hum Mol Genet. 2015 Jan 15; 24(2): 572-81. Epub 
2014 Sep 15. 
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Genome-wide association studies (GWAS) have identified seven loci associated with these 
measures in subjects of European descent (p<5x10
-8
) (20, 82-84), including the variants in or 
near TF-SRPRB, SLC17A1, HFE, HIST1H2BJ, SIK3, PCSK7, TMPRSS6. Here we present a 
genome-wide admixture and association study of serum iron, TIBC, SAT, and ferritin among 
African Americans (AA) enrolled in the JHS and HANDLS cohorts.  
 
Materials and methods 
Study Subjects  
Discovery Stage – The Jackson Heart Study (JHS) is a longitudinal, population-based cohort 
designed to identify risk factors for the development of CVD, T2D, obesity, chronic kidney 
disease and stroke in more than 5000 AAs from the Jackson, metropolitan area(85). The design, 
recruitment and initial characterization of this study have been described previously (86). The 
JHS participants for the current study included 1012 AA males and 1335 AA females with 
available iron-related measures and genome-wide genotype data.  
Replication Stage - The Healthy Aging in Neighborhoods of Diversity across the Life Span 
study (HANDLS) is a community-based, longitudinal epidemiological study that aims to 
examine the influences of race and socioeconomic status on the development of age-related 
diseases in African and European Americans from the city of Baltimore. The study consists of 
2200 AAs and 1522 European Americans aged 30-64. The design, recruitment, and initial 
characterization of this study have been described previously (87). The HANDLS participants 
for the current study included 329 AAs with iron measures and genome-wide genotype data.  
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    JHS and HANDLS participants provided written informed consent. The study protocols and 
consent forms for these studies were approved by the responsible research ethics committees and 
institutional research boards.  
Phenotypes  
All phenotype measures came from blood samples that were collected from fasting blood 
during the baseline examination, which occurred during 2000-2004 for JHS and 2004-2009 for 
HANDLS. Iron measures included total levels of serum iron (μg/dL), serum ferritin (ng/mL), 
TIBC (μg/dL) and SAT (%). Serum iron in JHS participants was measured by the FerroZine 
colorimetric assay (Roche), standardized to NIST traceable iron standards and calibrated against 
control sera from the manufacturer. TIBC was determined by colorimetric (FerroZine) 
measurement of iron that remains unbound after addition of a known amount of iron to the serum. 
The assay was standardized and calibrated as for serum iron. Ferritin was measured by an 
immunoturbidimetric assay (Roche) based on agglutination of anti-ferritin-latex conjugates, 
standardized with human spleen ferritin and calibrated against a standard protein solution 
provided by the manufacturer. For HANDLS, serum iron and TIBC were measured using 
standard clinical laboratory spectrophotometric assays. Serum ferritin was measured using 
chemiluminescence assays. For both studies, SAT was calculated as: (serum iron/TIBC)*100%.  
Participants were excluded if they were taking iron supplements or not fasting at time of 
blood draw and if they had known chronic infectious or inflammatory disease, or residual 
cancer.  Additional exclusions included hematocrit <35%, hemoglobin <11 g/dl, mean red cell 
volume >100 fL, white blood cell count >11,000 /mm
3
, platelet count >400,000 /mm
3
, C-reactive 
protein > 3 standard deviations above the mean, or transferrin saturation < 15% (indicates iron 
deficiency likely due to blood loss). 
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Genotyping and Imputation 
A total of 3030 JHS participants were genotyped using the Affymetrix Genome-Wide Human 
SNP Array 6.0. 874,712 SNPs, with a call rate greater than 0.95, minor allele frequency (MAF) 
greater than 0.01, and genotype distributions consistent with Hardy-Weinberg equilibrium (HWE 
p >1x10
-5
) were included for further analysis. Following pre-phasing using MACH 1.0.18 
software (88), thirty-eight million SNPs, excluding SNPs monomorphic in CEU/YRI, were 
imputed using minimac (89) based on 1000 Genome Project phase I reference samples (Nov 
2010, Version 3). Analyses were limited to the ~17 million imputed SNPs with estimated 
imputation quality of r
2
 greater than 0.3.  
 A total of 1024 HANDLS participants were genotyped using the Illumina 1M SNP array, 
including 329 AAs with iron measures. SNPs with HWE p >1x10
-7
, MAF > 0.01, and call rate > 
95% were included for further analysis. 2,939,993 SNPs were imputed using MACH (88) and 
Minimac (89) software based on combined reference haplotype data from HapMap Phase 2 
CEU+YRI samples that includes monomorphic SNPs in either of the two constituent populations 
(release 22, build 36.3). Chromosome X variants were imputed based on 1000 Genomes Project 
EUR+AFR+AMR+ASN reference samples. Only index variants demonstrating significant 
evidence for association in JHS (p<5x10
-8
) were subsequently analyzed for the relevant iron 
phenotype in HANDLS. 
Statistical Analyses 
To assess the impact of genetic admixture on iron measures within the AA population, we 
first estimated the genome wide average of African ancestry for each JHS participant (“global 
ancestry”). We used the software ADMIXTURE (90) with K=2 clusters and tested, using linear 
models implemented in R, whether this estimated global ancestry proportion was associated with 
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each of our iron measures after covariate adjustments for age, sex, and BMI. Values of serum 
ferritin, total iron and SAT were natural log-transformed to achieve approximate normality of 
residuals. 
ANCESTRYMAP (72) was used to estimate local ancestry (probabilities of whether an 
individual has 0, 1, or 2 alleles of European ancestry) at 738,831 autosomal SNPs across the 
genome, for each participant in JHS, as previously described (91).  In brief, local ancestry was 
inferred using a hidden Markov model based on the genotypes from a panel of densely spaced 
markers differentiated in frequency between African and European populations. To assess 
whether there were any regions where local ancestry was associated with iron-related measures, 
we performed admixture mapping across the whole genome by regressing each of our iron 
measures on the local ancestry estimates at each SNP location, including covariate adjustment 
for age, sex, BMI and estimated global ancestry. The conventionally reported LOD score, 
defined as the log, base 10, ratio of the maximum likelihood of the data under a local-ancestry-
associated model divided by the likelihood of the data under the null model (with no local 
ancestry predictor), was computed at each SNP location. For regions showing association of 
increased African ancestry with higher levels of iron measures, the LOD scores were assigned 
positive values, and for regions showing association of increased African ancestry with lower 
level of iron measures, the LOD scores were assigned negative values. The LOD scores were 
plotted across the genome, and a LOD score of 5 was assumed to be the threshold of statistical 
significance (72).  
Individual genotyped and imputed SNPs were tested for association using multivariable 
linear regression models in PLINK (92) and MACH2QTL v.1.08 (88), respectively; adjusted for 
age, sex, BMI and 10 principal components that we constructed using the software EIGENSOFT 
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(93)  to model background ancestry. A second level of covariate adjustment for log-ferritin 
additionally included self-reported menopausal status, which was available on a large subset of 
JHS subjects and has been shown previously to be a strong predictor of serum ferritin levels (94, 
95). We assumed an additive mode of inheritance and reported  coefficients representing the 
estimated change in the raw or transformed trait value, associated with each additional copy of 
the effect allele. For chromosome X SNPs, hemizygous males were modeled so that males with 
the minor allele had the same value as females homozygous for the minor allele.  We used a 
significance threshold of p =5x10
-8
 to maintain an overall type 1 error rate of ~5% for each 
phenotype.  
Manhattan plots were made to illustrate the association results across the genome and 
quantile-quantile (Q-Q) plots were made to assess any systematic inflation of the regression test 
statistics across the genome. In regions demonstrating significant evidence for association, we 
examined multivariable regression models that included the genotype data of the most strongly 
associated SNP as a covariate to assess whether there was any evidence for multiple 
independently associated SNPs in a particular region. If a second signal also reached genome-
wide significance after conditioning on the top variant, multivariable regression models were 
repeated to include the genotypes of both SNPs as covariates. The relevant SNP-SNP 
interactions were also tested. Region-specific (“locus-zoom”) plots were made to show the 
magnitude of association between all SNPs and the relevant iron phenotype as well as the LD 
between each SNP in the region and the most strongly associated SNP. Finally, to control for 
possible confounding between SNP genotype and local ancestry in any observed iron trait-SNP 
associations, we identified the genetic position of the most strongly associated SNP, selected the 
local ancestry estimate at the location closest to that SNP (either the SNP itself if genotyped or 
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the closest genotyped SNP), and examined multivariable regression models as described above, 
but now including estimated local ancestry proportion as an additional covariate. 
SNPs that reached genome-wide significance in JHS were selected for testing in the 
replication study of HANDLS. At each associated region, only the single SNP with the most 
significant P value (index SNP) was selected to avoid over adjustment for multiple testing. For 
the TF region, where conditional analyses revealed a second independently associated SNP with 
TIBC, the second independent SNP was also included in the replication analyses.  A GWAS 
result was considered replicated if the effect in the replication was in the same direction as in the 
discovery stage, and if the association in the replication stage was statistically significant after 
Bonferroni correction adjusting for the number of SNPs tested.  
Ethnic differences in iron related measures have also been observed between subjects of 
European and African descent (96). Thus, we compared our association results in JHS with 
established variants from GWASs in populations of European descent in order to assess the 
importance of these same variants in an AA population. For each prior GWAS-established SNP, 
we identified and tested all genotyped or imputed proxy SNPs in JHS that were estimated to be 
in high LD (r
2
 > 0.8 in CEU based on 1000 Genomes data) with the GWAS index SNPs for 
association with the reported iron phenotype.  
 
Results 
Descriptive statistics for the JHS and HANDLS participants included in this study are 
detailed in Table 2.1. The correlations between these four phenotypes in JHS are shown in 
Table 2.2.  
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Admixture Analyses 
A higher level of estimated overall average African ancestry was significantly associated 
(p<0.05) with lower levels of TIBC, iron and SAT (Table 2.3). The estimated proportions of 
overall average African ancestry obtained from ADMIXTURE were highly correlated with the 
first principal component from EIGENSOFT (correlation = 0.998). No individual region had 
local ancestry significantly associated with the iron measures. Three regions (DZIP1L on chr 3, 
TRDN on chr 6, and TMCO5B-RYR3 on chr 15) had a LOD score >3 for TIBC, one region 
(DEFB129-DEFB132 on chr 20) had a LOD score >3 for iron. The plots of the LOD scores 
across the whole genome are shown in Figure 2.1. 
 
Summary GWAS Results in JHS 
One-hundred-fifty-seven SNPs reached genome-wide significance (p<5x10
-8
) for TIBC (153 
SNPs on chromosome 3, 3 SNPs on chromosome 6, and 1 SNP on chromosome 16); five SNPs 
were significant for ferritin (all on chromosome X). Top SNPs that reached genome-wide 
significance in JHS was shown in Table 2.4. No SNPs reached genome-wide significance for 
serum iron or SAT. Top results for all four traits are listed in Tables 2.5-2.8. Manhattan plots 
and Q-Q plots for the four traits are shown in Figure 2.2 and Figure 2.3. Q-Q plots revealed no 
substantial evidence for inflated results, due to population stratification, residual relatedness 
among subjects, or experimental outliers.  
 
TIBC GWAS Results on Chromosome 3 
All top SNPs on chromosome 3 clustered within a region spanning less than 150 kb 
containing 3 genes: TOPBP1, TF, and SRPRB (Figure 2.4). The strongest signal (rs8177253, 
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p=1.8×10
-47
, MAF=0.24) mapped to the TF gene, which encodes transferrin. Rs8177253 was 
also nominally associated with SAT (p=3.0x10
-7
). Thirty-six TF region SNPs were genome-wide 
significant for TIBC levels after conditional analysis including rs8177253 as a covariate (Table 
2.9). The top SNP in the conditional analysis was rs9872999 (p=5.4x10
-20
, MAF=0.38), which 
was not significant (p=1.0x10
-6
) prior to the adjustment for rs8177253 (Table 2.9; Figure 2.4). 
There was no evidence of an interaction between the rs8177253 and rs9872999 (p=0.11). No 
SNPs remained genome-wide significant after covariate adjustment for both rs8177253 and 
rs9872999, though a large number of SNPs remained nominally significant. SNP rs8177253 and 
rs9872999 together explained an estimated 11.2% of the total variance of TIBC after accounting 
for age, gender, BMI, and the first 10 PCs. 
Higher local African ancestry in the TF region was nominally associated with lower TIBC 
levels (p=0.0012). The association between TIBC and rs8177253 remained robust after the 
adjustment for local African ancestry at rs8177253. When stratified by the estimated local 
number of European versus African chromosomes, the rs8177253-TIBC association was present 
among 1579 AA who were predicted to carry two African chromosomes (β= 19.64 ± 1.70; 
p=8.5x10
-30
) as well as the 768 AA who were predicted to carry at least one European 
chromosome (β = 19.68 ± 2.26; p=1.8x10-17). The rs9872999-TIBC association also remained 
significant after adjustment for both rs8177253 and local African ancestry at the genotyped 
marker nearest its location (data not shown). 
 
TIBC GWAS Results on Chromosome 6 
The three genome-wide significant SNPs on chromosome 6 mapped near the HDGFL1 gene 
(Figure 2.5). The strongest signal (rs115923437, p=1.1x10
-8
) mapped ~100Kb distal to 
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HDGFL1, which is a gene that encodes hepatoma derived growth factor-like 1 and is associated 
with glycosylated hemoglobin level, and ~3.5Mb proximal to the known iron gene HFE. After 
conditioning on rs115923437, the remaining SNPs within 1Mb of the SNP no longer showed 
strong evidence for association (all p>1x10
-4
). SNP rs115923437 explained 1.3% of the total 
variance of TIBC after accounting for the covariates. 
Local African ancestry in the HDGFL1 region also showed a nominally significant 
association with TIBC, though this time higher local African ancestry was associated with higher 
TIBC levels (p=0.0083). The associations between TIBC and rs115923437 remained significant 
after the adjustment for local African ancestry at the genotyped marker nearest its location. 
When stratified by the estimated local number of European versus African chromosomes, the 
rs115923437-TIBC association was present among the 1569 AA who were predicted to carry 
two African chromosomes (β = -14.11 ± 2.95; p=2.0x10-6), as well as the 778 AA who were 
predicted to carry at least one European chromosome (β = -15.42 ± 5.78; p=0.0070). 
 
TIBC GWAS results on chromosome 16 
A single SNP (rs16951289, p=2.0x10
-8
) on chromosome 16, an intronic variant in 
uncharacterized gene LOC102467146 that is ~150Kb distal to the MAF gene (Figure 2.6), 
reached genome-wide significance. MAF encodes v-maf musculoaponeurotic fibrosarcoma 
oncogene homolog. Local African ancestry in this region was not associated with TIBC (p=0.97) 
and did not modify the evidence for association with rs16951289. Rs16951289 explained 1.2% 
of the total variance of TIBC. 
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Ferritin GWAS results on chromosome X 
 Five SNPs on chromosome X near the GAB3 gene reached genome-wide significance for 
association with ferritin levels (Figure 2.7). The strongest signal (rs141555380, p=1.1x10
-8
), 
mapped to the UTR-3 region of the GAB3 gene. GAB3 encodes GRB2-associated binding protein 
3, which is involved in several growth factor and cytokine signaling pathways. After 
conditioning on rs141555380, the remaining SNPs within 1Mb of rs141555380 no longer 
showed significant evidence for association (all p>1x10
-4
). The effect estimates for carriers of the 
rs141555380 minor allele in stratified analysis were similar for hemizygous males and 
homozygous females (hemizygous males: β = 0.17±0.04, p = 5.05 x 10-6; homozygous females: 
β = 0.14±0.05, p = 0.002). SNP rs141555380 explained 1.2% of the total variance of ferritin after 
accounting for age, gender, BMI and the first 10 PCs.  
 
Menopause status-Adjusted analyses of association with ferritin 
Association analysis for serum ferritin was conducted by including menopausal status as an 
additional covariate. Menopausal status was significantly associated with serum ferritin levels p= 
5.3x10
-17
, however, the effect size and significance of SNP-ferritin associations did not change 
considerably after adjusting for menopausal status. The top SNP rs141555380 (p=1.1x10
-8
) 
continued to be the most significant SNP after adjusting for menopause status (p=1.4x10
-8
). The 
effect sizes and P-values of top SNPs (p<10
-7
) before and after adjusting for menopause status 
are shown in Table 2.10 This result is consistent with previous findings that the effects of 
variation in menstrual blood loss, although significant, were small when compared to the genetic 
effects that influence the iron reserves (94).  
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Replication Results in HANDLS 
      Four regions contained SNPs that reached genome-wide significance in GWASs in JHS, 
including one region, the chromosome 3 TF region, which contained a second significant SNP 
(rs9872999) after covariate adjustment for the top SNP (rs8177253). Five SNPs (rs8177253, 
rs9872999, chromosome 6 top SNP rs115923437 and chromosome 16 top SNP rs16951289 for 
TIBC; chromosome X top SNP rs141555380 for ferritin) were selected and tested for association 
in HANDLS to determine whether the associations could be replicated (Table 2.4). Rs9872999 
was tested before and after adjustment for rs8177253. Both associations in the TF region with 
TIBC were replicated (p=1.1x10
-7 
for rs8177253; p=0.0012 for rs9872999 before adjusting for 
rs8177253). As with JHS, the association between rs9872999 and TIBC became more significant 
after adjusting for the primary signal at rs8177253 (p=6.2x10
-6
). The association between the 
GAB3 region SNP rs141555380 and ferritin also replicated (p=5.7x10
-3
). The associations 
between TIBC and SNPs rs115923437 and rs16951289 did not replicate in HANDLS; 
rs16951289 was nominally significant (p=0.04), but the direction of the effect went in the 
opposite direction to that observed in JHS.  
Prior European GWAS-established signals at p<5x10
-8
 that are replicated in JHS at p<0.05 
GWAS have reported five regions to contain SNPs to be significantly associated (p<5x10
-8
) 
with at least one of the following iron-related traits: iron, ferritin, SAT and transferrin, including 
TF-SRPRB (rs3811647, rs1830084), SLC17A1 (rs17342717), HFE (rs1799945 [H63D] and 
rs1800562 [C282Y]), HIST1H2BJ (rs13194491), and TMPRSS6 (rs855791 [V736A] and 
rs4820268) in subjects of European descent (Table 2.11). Iron, ferritin, and SAT are directly 
reported in the current study while TIBC is proportional to transferrin [TIBC (μmol/L) = 25.1 × 
transferrin (g/L)]. All five regions contained a SNP, either the index SNP in the prior report or a 
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SNP in strong linkage disequilibrium (defined as estimated r
2
>0.8 with the index SNP based on 
CEU 1000 Genomes subjects) with the index SNP, that was nominally associated with at least 
one corresponding iron measure in JHS at p<0.05. For HFE rs1800562, only the associations 
with ferritin and transferrin were replicated, but not the associations with iron and SAT. For  
HIST1H2BJ rs13194491 and TMPRSS6 rs855791, the associations with the index SNPs were not 
replicated, but nearby SNPs, which are estimated to be in high LD with index SNPs in European 
populations, did reach nominal significance in JHS, suggesting a narrowing of the candidate 
regions for the causal variants if the causal variants are the same for the two populations.  
 
Discussion 
We conducted genome-wide admixture and association studies for iron-related phenotypes 
including serum iron, serum ferritin, SAT, and TIBC in 2347 AAs participating in the Jackson 
Heart Study. We observed significant associations between SNPs around TF, a well-established 
region on chromosome 3, and two novel regions: near HDGFL1 on chromosome 6 and MAF on 
chromosome 16, and TIBC levels. Conditional analyses revealed a second significant SNP 
associated with TIBC in the TF region that was independent of the top SNP from the 
unconditional analyses. We also observed significant associations between SNPs around GAB3, 
a novel region on chromosome X, and ferritin levels. The two independent associations for TIBC 
at TF and the association for ferritin at GAB3 were successfully replicated in HANDLS. The 
associations between the JHS index SNPs near HDGFL1 and MAF were not replicated. The 
available sample size in HANDLS (N=329) was considerably smaller than for JHS. If we assume 
the index variants at HDGFL1 and MAF each explain an estimated 1.3% of the total variance of 
TIBC, then we only had power of 0.34 to observe these associations at p<0.01 in HANDLS.  
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Thus, larger replication studies will be necessary to make more decisive statements regarding the 
overall evidence in these other regions. We did not observe any significant SNP associations for 
the other iron measures, though we were able to replicate associations from previous studies 
based on subjects of European descent using a less stringent significance threshold (p<0.05).  
The estimated average (“global”) proportion of African ancestry was significantly associated 
with lower levels of TIBC, serum iron, and SAT - which are entirely consistent with previous 
findings reporting lower levels of these same measures, on average, in AAs compared to 
European Americans (96, 97).  Subjects with higher levels of global African ancestry were 
observed to have higher levels of ferritin, also consistent with prior reported differences between 
individuals of European and African ancestry (96, 97), although this result was not statistically 
significant. These results implicate novel genetic risk factors in AAs and underscore the 
importance of studying this population for genetic risk factors that uniquely/disproportionately 
impact them. Local ancestry was not significantly associated with any iron measures, though a 
couple regions containing our GWAS top results were nominally significant. 
Variants in and around TF have been observed to be associated with serum ferritin levels 
(20), transferrin levels (20, 83, 84), serum transferrin saturation (22), and serum levels of 
carbohydrate-deficient transferrin (CDT) (98) in subjects of European descent. In JHS, the top 
SNP at TF, rs8177253, was associated with TIBC (p=1.8x10
-47
) and nominally associated with 
SAT (p=3.0x10
-7
). SNP rs8177253 is located in an intronic region of TF, and is in high LD (r
2
=1, 
D’=1 in 1000 Genomes CEU) with GWAS index SNP rs3811647 previously reported to be 
associated with transferrin in European Americans (rs3811647 is also associated with TIBC 
[p=9.7x10
-35
] and nominally associated with SAT [p=2.2x10
-6
]
 
in JHS). After conditioning on 
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rs8177253, all SNPs, including rs3811647, previously reported to be significantly associated 
with TIBC became non-significant in JHS.  
Our study is the first study to report a second significant independently associated SNP in the 
TF region for TIBC. Interestingly, this second signal (index SNP rs9872999 which maps to an 
intergenic region approximately 10Kb proximal to TF) only became significant at the genome-
wide level after conditioning on our top TF region SNP rs8177253. Rs8177253 and rs9872999 
are in modest LD in 1000 YRI Genomes subjects (r
2=0.07,D’=0.58) and in stronger LD in 1000 
Genomes CEU subjects (r
2=0.27,D’=0.71). The allele associated with an increase in TIBC for 
rs8177253 is preferentially on the same haplotype with the allele associated with a decrease in 
TIBC for rs9872999. Thus, the mean effects for rs9872999 are shrunk towards the null when not 
factoring in genotype for rs8177253. There is no evidence for an interaction between these SNPs 
on TIBC levels, thus the results indicate a second independent signal in the TF region. It is 
unclear if this second signal is specific to African Americans, as results from conditional 
analyses in other populations have not been reported. Conditional analyses would likely be 
especially important in populations of European descent given the stronger LD between the two 
SNPs in this population. The minor allele frequency for rs9872999 is 0.39 in 1000 Genomes YRI 
subjects and 0.50 in 1000 Genomes CEU subjects.  
Variants in HDGFL1 have been reported previously to be associated with glycosylated 
hemoglobin levels (p=2.4x10
-5
) in European type 1 diabetic subjects (99) and nominally 
associated (p<0.05) with levels of VLDL, LDL, Apolipoprotein C, HDL, and carotid artery 
disease (100-102). In recent years there has been considerable interest in the possibility that 
excessive tissue iron stores may contribute to the pathogenesis of both diabetes and ischemic 
heart disease (19). MAF, which encodes v-maf musculoaponeurotic fibrosarcoma oncogene 
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homolog, appears to be important in early development. Mutations in MAF have been reported to 
co-segregate with cerulean congenital cataracts (103) and juvenile-onset pulverulent cataract 
(104) in human pedigrees. We can find no evidence in the literature suggesting a direct 
connection between MAF and iron metabolism. However, there is some evidence of pleiotropy 
for iron metabolism and cataracts, namely hereditary hyperferritinemia cataract syndrome 
(HHCS), which is an inherited syndrome caused by a mutation within the L-ferritin gene and 
characterized by early-onset cataracts and elevated serum ferritin (105).  
A cluster of SNPs near GAB3 on chromosome X were significantly associated with ferritin 
(top SNP rs141555380, MAF=0.14, p=1.1x10
-8
) and nominally associated with SAT 
(rs141555380, p=0.037). Although no prior studies observed any connection between this gene 
and iron metabolism, another gene ~0.2 Mb upstream of GAB3, G6PD, plays a critical role in 
iron metabolism. G6PD deficiency may cause acute hemolysis or severe chronic non-spherocytic 
hemolytic anemia. Increases in serum ferritin levels have been observed in G6PD-deficient 
patients (106, 107), which is possibly due to both a shortened life-span and increased break down 
of erythrocytes in G6PD-deficient patients. A functional missense variant in G6PD, rs1050828 
(MAF=0.13, leading to a Val68Met amino acid substitution), was also associated with ferritin 
but narrowly missed genome-wide significance (p=9.1x10
-8
). Strong LD exists between this 
functional variant at G6PD and rs141555380 (R
2=0.91, D’=1 in 1000 Genomes Project 
participants of African descent), and the association between rs141555380 and ferritin disappears 
after adjustment for rs1050828 (p = 0.55). Rs1050828 and nearby rs762516 (two SNPs in LD: 
R
2=0.68, D’=1.0 in HapMap YRI) have been shown to be significantly associated with multiple 
erythrocyte traits in AAs, including hematocrit, hemoglobin, red blood cell (RBC) count, mean 
corpuscular volume (MCV), and red cell distribution width (RDW) in previous GWAS or 
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candidate gene studies (108, 109). In JHS, rs1050828 is significantly associated with MCV 
(p=1.7x10
-8
), RBC count (p=9.9x10
-16
), and RDW (p=8.9x10
-21
) and nominally associated with 
hematocrit (p=8.7x10
-7
) and hemoglobin (7.1x10
-8
). Ferritin levels are correlated with levels of 
hematocrit (r=0.25), hemoglobin (r=0.27), MCV (r=0.089), RBC (r=0.15) and RDW (r=-0.13). 
The associations for both hematocrit (p=2.9x10
-8
) and hemoglobin (p=4.3x10
-10
) both became 
genome-wide significant after additional covariate adjustment for ferritin. Similarly, the 
association between rs1050828 and ferritin also became genome-wide significant after 
adjustment for hematocrit (7.2x10
-9
) and hemoglobin (1.3x10
-9
), but evidence for association 
with ferritin decreased after covariate adjustment for MCV (1.1x10
-4
), RBC (5.2x10
-6
) and RDW 
(7.2x10
-3
).  Since G6DP has been reported to play an important role in hemolysis and affect the 
levels of erythrocyte traits, the signal we observed at this region may help explain the 
relationship between hemolysis and iron metabolism. This variant is also implicated in malaria 
resistance, and the A- form of G6PD deficiency in Africa is under strong natural selection from 
the preferential protection it provides to hemizygous males and homozygous females against life-
threatening malaria (110). This natural selection of G6PD deficiency in African descent may 
help explain the marked differences in iron measures among ethnic groups. 
In summary, we report that global genetic admixture is an important predictor of iron 
measures in AAs, further implicating the importance of unique genetic effect alleles in the AA 
population. We observed SNPs in or near three genes, TF, HDGFL1 and MAF, which were 
significantly associated with TIBC in JHS, and SNPs near GAB3 that were significantly 
associated with ferritin. We identified a novel second independently associated SNP in the TF 
region for TIBC that was only identified after conditioning on the top SNP in the region. The two 
TF and the GAB3 signals were replicated in a small independent AA sample from HANDLS. 
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Larger replication samples will be necessary to draw firm conclusions regarding the associations 
for the other loci.  The TF region is known to be associated with various serum iron-related 
measures in subjects of European descent; we now show similar associations in AA. While the 
G6DP-GAB3 region is known to be associated with multiple erythrocyte traits in AA, this is the 
first time it has been reported to be significantly associated with ferritin, a specific iron-related 
measure in AA. We have also nominally replicated four other established loci from other 
populations in our AA samples. Future fine-mapping studies, including rare and uncommon 
variants, and functional studies should be undertaken to better characterize these and other loci 
and ultimately to identify the functional variants directly influencing iron levels in AA. 
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Table 2.1 Descriptive statistics of JHS and HANDLS participants for the study of iron-related phenotypes 
  
JHS 
  
HANDLS 
 
 
Total Male Female Total Male Female 
Sample size 2347 1012 1335 329 189 140 
Age (years)   54.5 ± 12.6   53.0 ± 12.8   55.7 ± 12.4 49.4 ± 8.3 49.0 ± 8.7 49.9 ± 7.7 
BMI (kg/m2) 31.5 ± 6.9 29.9 ± 6.1 32.8 ± 7.3 28.8 ± 7.6 27.1 ± 5.4 31.2 ± 9.3 
Ferritin (ng/mL) 134.0 (74.0, 232.0) 177.5 (110.8, 286.0)    105 (58.0, 185.5)  107.5 (54.0, 201.0) 137.0 (76.0, 257.0)   71.0 (35.0, 113.0) 
Iron (μg/dL) 81.0 (67.0, 98.0)     86.0 (70.0, 104.0) 78.0 (64.0, 94.0)     83.0 (66.2, 103.8)   86.0 (70.0, 109.0) 81.0 (64.0, 98.0) 
SAT (%) 28.0 (23.0, 35.0)   30.0 (25.0, 37.0) 27.0 (22.0, 33.0) 25.0 (20.2, 31.1) 26.4 (20.8, 33.5) 23.7 (19.3, 27.3) 
TIBC (μg/dL) 284 (260.0, 314.0) 280.0 (256.0, 307.0) 288.0 (263.0, 319.0) 332.0 (306.0, 372.0) 326.0 (300.0, 368.0) 342.5 (316.8, 379.0) 
 
Data are mean±SE, median (25th, 75th percentiles) 
SAT: Transferrin saturation; TIBC: Total iron binding capacity 
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Table 2.2 Correlation between iron-related phenotypes 
 
TIBC log_ferritin log_iron log_sat 
TIBC 1.00 -0.32 0.20 -0.29 
log_ferritin 1.00 0.08 0.23 
log_iron 
  
1.00 0.88 
log_sat 
   
1.00 
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Table 2.3 Association between global African ancestry estimate and iron-related 
phenotypes 
 
Phenotypes β* SE P 
TIBC -13.90 6.80 0.04 
log_ferritin 0.13 0.13 0.32 
log_iron -0.20 0.05 2.4E-05 
log_SAT -0.15 0.05 0.0019 
 
* The predicted change in the iron measure for each one-percentage point increase in estimated 
global African ancestry. 
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Table 2.4 Top SNPs that significantly (p<5x10
-8
) associated with iron-related phenotypes in JHS and replication results from 
HANDLS. 
                  
      JHS HANDLS 
Trait Chr Nearest Gene SNP Pos(hg19) EA EAF N R2 β SE P EAF N R2 β SE P 
TIBC 3 TF rs8177253 133480192 T 0.24 2347 NA 19.86 1.34 1.8E-47 0.23 329 0.98 26.72 4.91 1.1E-07 
TIBC 3 TF rs9872999 133457514 T 0.62 2347 0.80 -6.55 1.34 1.1E-06 0.60 329 0.93 -14.19 4.33 0.0012 
TIBC 3 TF rs9872999* 133457514 T 0.62 2347 0.80 -11.72 1.28 5.4E-20 0.60 329 0.93 -19.11 4.16 6.2E-06 
TIBC 6 HDGFL1 rs115923437 22678302 C 0.06 2347 0.91 14.84 2.6 1.1E-08 0.05 329 0.96 -5.28 9.93 0.60 
TIBC 16 MAF-DYNLRB2 rs16951289 79790621 T 0.07 2347 0.91 13.38 2.38 2.0E-08 0.08 329 0.97 -15.95 7.92 0.04 
Log_ferritin X GAB3 rs141555380 153906012 T 0.14 2347 0.94 0.17 0.03 1.1E-08 0.13 329 0.98 0.24 0.08 0.0057 
 
*: β, SE, and P were reported for rs9872999 after adjusting for rs8177253. 
Chr: chromosome; Pos(hg19): physical position of the SNP according to human genome build version 19; EA: effect allele; EAF: 
effect allele frequency; :  coefficients representing the estimated change in the raw or transformed trait value associated with each 
additional copy of the effect allele; SE: standard error; R
2
: R
2
 represents the imputation quality provided by minimach. “NA” indicates 
that the actual genotype data from Affy 6.0 array were used in the analyses.  
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Table 2.5 Top SNPs associated with TIBC at P<10
-6 
 
Chr Nearest Gene # of SNPs Most Significant SNP Pos(hg19) EA EAF β SE P Imputed (Y/N) R2 Function 
1 BAI2 1 rs182815963 32219928 T 0.00 -93.66 18.51 4.2E-07 Y 0.44 intronic 
2 SERTAD2-LOC400958 7 rs185183332 64967342 A 0.03 -20.46 4.01 3.3E-07 Y 0.69 intergenic 
2 RPRM-GALNT13 2 rs189855038 154428028 C 0.00 -90.97 17.96 4.1E-07 Y 0.31 intergenic 
3 LOC440970 1 3:84190898:A_AT 84190898 AT 0.02 37.67 7.59 6.9E-07 Y 0.36 intergenic 
3 TF 221 rs8177253 133480192 T 0.24 19.86 1.34 1.8E-47 N NA intronic 
4 DCK-SLC4A4 1 rs147549040 72028308 G 0.00 85.49 17.17 6.4E-07 Y 0.39 intergenic 
6 HDGFL1-NRSN1 10 rs115923437 22678302 C 0.06 14.84 2.60 1.1E-08 Y 0.91 intergenic 
6 MIR5695 1 rs112647290 126435741 T 0.03 23.52 4.67 4.7E-07 Y 0.58 intronic 
10 FRMD4A-MIR1265 1 rs59376103 14442418 T 0.04 -17.36 3.37 2.6E-07 Y 0.78 intergenic 
10 KCNMA1 2 rs71475649 79082679 C 0.01 70.63 13.65 2.3E-07 Y 0.33 intronic 
11 LUZP2 1 rs61877888 24602715 G 0.15 9.36 1.87 5.3E-07 Y 0.80 intronic 
13 SLITRK1 2 rs192989741 83958956 G 0.00 -76.76 15.20 4.4E-07 Y 0.38 intergenic 
13 ATP11A-MCF2L-AS1 1 rs114067519 113547283 C 0.04 22.38 4.48 5.9E-07 Y 0.41 intergenic 
16 IGFALS-HAGH 1 rs2256923 1844781 G 0.72 -9.98 2.04 9.9E-07 Y 0.41 intergenic 
16 SLX4-DNASE1 1 rs60860998 3690092 C 0.03 32.70 6.47 4.3E-07 Y 0.33 intergenic 
16 MAF-DYNLRB2 2 rs16951289 79790621 T 0.07 13.38 2.38 2.0E-08 Y 0.91 intergenic 
18 PTPN2-SEH1L 1 rs73407743 12943299 A 0.10 11.06 2.25 9.0E-07 Y 0.73 intergenic 
21 ADAMTS5-MIR5009 1 rs13052896 28481882 G 0.08 11.04 2.25 9.8E-07 Y 0.83 intergenic 
21 HUNK 1 21:33316076:CCTT_ 33316076 C 0.04 18.04 3.63 6.5E-07 Y 0.74 intronic 
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Table 2.6 Top SNPs associated with log_ferritin at P<10
-6 
 
Chr Nearest Gene # of SNPs Most Significant SNP Pos(hg19) EA EAF β SE P Imputed (Y/N) R2 Function 
1 RCC2-ARHGEF10L 1 rs2477740 17831605 A 0.82 0.19 0.04 3.9E-07 Y 0.65 intergenic 
3 FHIT 1 rs13074132 60321082 C 0.18 0.16 0.03 3.0E-07 Y 0.92 intronic 
10 RSU1 1 rs76969309 16824397 A 0.05 0.33 0.06 8.3E-08 Y 0.72 intronic 
10 ADRA2A-GPAM 1 rs17129425 113727270 G 0.19 -0.16 0.03 3.9E-07 Y 0.87 intergenic 
18 CEP192 1 rs1787009 13063889 A 0.13 -0.20 0.04 7.6E-07 Y 0.76 intronic 
19 C19orf18 4 rs192471137 58469524 A 0.00 1.72 0.32 1.2E-07 Y 0.40 intergenic 
X G6PD-GAB3 21 rs141555380 153906012 T 0.14 0.17 0.03 1.1E-08 Y 0.94 UTR-3 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
4
0
 
Table 2.7 Top SNPs associated with log_iron at P<10
-6 
 
Chr Nearest Gene # of SNPs Most Significant SNP Pos(hg19) EA EAF β SE P Imputed (Y/N) R2 Function 
2 ERBB4 5 rs139713297 212423072 A 0.00 0.74 0.14 1.6E-07 Y 0.33 intronic 
2 SPHKAP-PID1 1 rs1727563 229669613 T 0.31 -0.06 0.01 6.1E-07 Y 0.59 intergenic 
4 CC2D2A 1 rs188125026 15490175 C 0.00 1.61 0.32 5.2E-07 Y 0.37 intronic 
4 SLIT2 3 rs143034438 20560387 A 0.01 0.28 0.05 8.7E-08 Y 0.48 intronic 
4 HSP90AB3P-SPP1 1 rs143957415 88837386 T 0.03 0.15 0.03 2.1E-07 Y 0.65 intergenic 
8 EPHX2-CLU 5 rs79882106 27414335 C 0.00 0.80 0.15 8.0E-08 Y 0.32 intergenic 
8 EYA1-MSC 1 rs191222090 72718862 G 0.00 0.49 0.10 6.2E-07 Y 0.44 intergenic 
15 SPRED1 1 rs1522782 38544590 G 0.88 -0.08 0.02 3.8E-07 Y 0.63 intergenic 
15 LINC00052-NTRK3 1 rs139196658 88173631 T 0.00 1.50 0.31 8.6E-07 Y 0.36 intergenic 
16 RBFOX1 1 rs2109459 6440752 T 0.47 0.05 0.01 6.2E-07 Y 0.64 intronic 
16 ZCCHC14 1 16:87446849 87446849 C 0.00 0.82 0.16 2.3E-07 Y 0.37 intronic 
X HTATFS1-VGLL1 1 rs184017266 135612099 A 0.00 31.47 6.26 4.9E-07 Y 0.35 intergenic 
X SETP8 2 rs190571075 116387808 T 0.00 2.86 0.58 8.0E-07 Y 0.32 intergenic 
X HTR2C-IL13RA2 1 rs140631409 114166154 T 0.00 0.95 0.19 8.6E-07 Y 0.53 intergenic 
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Table 2.8 Top SNPs associated with log_SAT at P<10
-6 
 
Chr Nearest Gene # of SNPs Most significant SNP Pos(hg19) EA EAF β SE P Imputed (Y/N) R2 Function 
1 LOC100129138-PRMT6 1 rs113982601 106475276 A 0.10 0.09 0.02 9.4E-07 Y 0.56 intergenic 
2 SPHKAP-PID1 1 rs6756903 229646101 C 0.31 -0.06 0.01 6.5E-07 Y 0.64 intergenic 
2 NGEF 1 rs938575 233768788 A 0.10 -0.07 0.02 3.9E-07 Y 0.88 intronic 
3 TF 4 rs6762719 133480817 G 0.24 -0.05 0.01 5.1E-07 Y 1.00 intronic 
5 LSM11 1 rs145829393 157176316 T 0.02 0.25 0.05 7.8E-07 Y 0.44 intronic 
8 CSMD1-LOC100287015 1 rs140656346 5682652 G 0.00 0.55 0.11 6.1E-07 Y 0.34 intergenic 
8 MFHAS1-ERI1 1 rs115730735 8820986 T 0.05 0.13 0.03 8.7E-07 Y 0.60 intergenic 
10 RHOBTB1 9 rs112298642 62634356 T 0.00 0.39 0.07 2.1E-07 Y 0.60 intronic 
13 KLF12-LINC00381 1 rs67180317 74869018 G 0.27 0.06 0.01 2.9E-07 Y 0.67 intergenic 
14 ESRRB-VASH1 1 rs75838009 77065324 T 0.02 0.21 0.04 1.1E-07 Y 0.75 intergenic 
15 SPRED1 1 rs1522782 38544590 G 0.88 -0.08 0.02 4.8E-07 Y 0.63 intergenic 
15 CKMT1A-CATSPER2P1 1 rs150805357 44016403 C 0.01 -0.30 0.06 6.3E-07 Y 0.53 intergenic 
16 ZCCHC14 1 16:87446849 87446849 C 0.00 0.86 0.16 1.2E-07 Y 0.37 intronic 
17 ASIC2-CCL2 1 rs142195977 32540548 T 0.03 -0.18 0.04 6.1E-07 Y 0.46 intergenic 
19 SMARCA4 1 rs116337692 11107134 A 0.07 -0.10 0.02 6.2E-07 Y 0.63 intronic 
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Table 2.9 SNPs on Chromosome 3 that significantly (P<5x10
-8
) associated with TIBC after adjusting for the top variant 
rs8177253 
 
     Before adjusting for rs8177253 After adjusting for rs8177253    
Nearest Gene MARKER Pos(hg19) EA EAF β SE P β SE P Imputed(Y/N) R2 Function 
TOPBP1 rs112327474 133348668 A 0.03 23.15 4.87 1.96E-06 25.74 4.65 3.13E-08 Y 0.48 intronic 
TOPBP1 rs113969369 133348677 A 0.03 23.17 4.86 1.87E-06 25.78 4.65 2.90E-08 Y 0.48 intronic 
TOPBP1-TF rs79213250 133391145 A 0.03 22.77 4.75 1.62E-06 25.41 4.54 2.16E-08 Y 0.55 intergenic 
TOPBP1-TF rs6806769 133431627 A 0.10 9.56 2.31 3.58E-05 13.24 2.21 2.12E-09 Y 0.69 intergenic 
TOPBP1-TF rs9830001 133433470 G 0.31 7.05 1.28 4.34E-08 7.04 1.23 1.06E-08 N NA intergenic 
TOPBP1-TF rs4078166 133435979 A 0.66 -6.73 1.33 4.23E-07 -11.03 1.27 4.11E-18 Y 0.86 intergenic 
TOPBP1-TF rs6782434 133438834 G 0.66 -6.76 1.33 3.46E-07 -11.06 1.27 2.65E-18 Y 0.87 intergenic 
TOPBP1-TF rs4443173 133439378 G 0.74 -4.65 1.39 8.19E-04 -7.37 1.33 2.75E-08 Y 0.90 intergenic 
TOPBP1-TF rs9843635 133440977 T 0.65 -6.71 1.35 6.42E-07 -11.29 1.29 1.85E-18 Y 0.83 intergenic 
TOPBP1-TF rs11921527 133441167 A 0.52 -0.84 1.26 5.06E-01 -6.81 1.20 1.51E-08 Y 0.85 intergenic 
TOPBP1-TF rs13066859 133442939 G 0.58 -6.65 1.41 2.43E-06 -10.97 1.35 4.20E-16 Y 0.71 intergenic 
TOPBP1-TF rs145713832 133445820 C 0.51 -8.14 1.49 4.63E-08 -10.40 1.42 2.72E-13 Y 0.62 intergenic 
TOPBP1-TF rs6804904 133447231 G 0.62 -6.30 1.34 2.83E-06 -11.08 1.29 6.41E-18 Y 0.80 intergenic 
TOPBP1-TF rs6439432 133448242 A 0.56 -5.51 1.39 7.54E-05 -9.17 1.33 5.44E-12 Y 0.72 intergenic 
TOPBP1-TF rs9820225 133449189 G 0.66 -6.77 1.31 2.26E-07 -10.94 1.25 2.08E-18 Y 0.89 intergenic 
TOPBP1-TF rs6439434 133450371 G 0.66 -6.45 1.28 5.00E-07 -10.81 1.23 1.18E-18 Y 0.93 intergenic 
TOPBP1-TF rs9869311 133451613 T 0.66 -6.48 1.28 3.75E-07 -10.79 1.22 8.74E-19 Y 0.94 intergenic 
TOPBP1-TF rs6439436 133453779 T 0.36 4.67 1.23 1.57E-04 9.75 1.21 1.07E-15 N NA intergenic 
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TOPBP1-TF rs150431546 133455441 G 0.66 -6.69 1.29 2.05E-07 -11.01 1.23 3.96E-19 Y 0.92 intergenic 
TOPBP1-TF rs9872999 133457514 T 0.62 -6.55 1.34 9.97E-07 -11.72 1.28 5.44E-20 Y 0.80 intergenic 
TOPBP1-TF rs79354095 133458401 A 0.66 -6.82 1.31 1.99E-07 -11.29 1.25 2.30E-19 Y 0.89 intergenic 
TOPBP1-TF rs4854596 133459260 C 0.66 -6.81 1.31 2.02E-07 -11.08 1.25 9.02E-19 Y 0.89 intergenic 
TOPBP1-TF rs10935085 133459735 T 0.64 -4.86 1.28 1.51E-04 -9.54 1.23 6.50E-15 Y 0.91 intergenic 
TOPBP1-TF rs8177177 133463195 C 0.49 -0.21 1.18 8.61E-01 -6.74 1.20 1.95E-08 N NA intergenic 
TOPBP1-TF rs8177179 133463457 A 0.66 -6.88 1.29 9.62E-08 -11.12 1.23 1.78E-19 Y 0.92 intergenic 
TOPBP1-TF rs8177182 133464314 A 0.10 4.93 2.18 2.37E-02 11.54 2.09 3.19E-08 Y 0.80 intergenic 
TF rs1130459 133465283 G 0.66 -7.00 1.30 7.43E-08 -11.27 1.24 1.27E-19 Y 0.90 UTR-5 
TF rs148600419 133467945 T 0.10 5.11 2.23 2.21E-02 11.67 2.13 4.47E-08 Y 0.78 intronic 
TF rs8177235 133476083 A 0.06 -17.69 2.48 1.37E-12 -13.35 2.40 3.10E-08 N NA intronic 
TF rs8177237 133476421 G 0.35 0.62 1.32 6.41E-01 -7.49 1.27 3.28E-09 Y 0.86 intronic 
TF rs8177257 133480337 T 0.03 -26.19 3.76 3.33E-12 -19.73 3.60 4.06E-08 Y 0.82 intronic 
TF rs2715632 133485830 T 0.31 1.34 1.26 2.87E-01 9.48 1.29 2.64E-13 N NA intronic 
TF rs2718806 133486093 A 0.40 3.49 1.19 3.43E-03 7.15 1.14 3.59E-10 Y 0.97 intronic 
TF rs8649 133486958 C 0.31 1.57 1.25 2.10E-01 8.27 1.19 4.15E-12 Y 0.99 exonic 
TF rs1358022 133487621 G 0.31 1.51 1.26 2.31E-01 9.61 1.28 1.02E-13 N NA intronic 
TF rs1358021 133488877 C 0.54 12.21 1.21 6.62E-24 6.32 1.16 5.05E-08 Y 0.90 intronic 
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Table 2.10 Effect sizes and P values for top SNPs associated with log_ferritin (p<10
-7
) in JHS before and after adjusting for 
menopause status.  
 
       
Before Adjustment 
  
After Adjustment 
 
 
Chr SNP EA EAF RSQR β SE P β SE P 
 
X rs141555380 T 0.14 0.94 0.17 0.03 1.1E-08 0.16 0.03 1.4E-08 
 
X rs7885619 G 0.15 0.94 0.17 0.03 1.9E-08 0.16 0.03 2.1E-08 
 
X rs7063597 T 0.14 0.94 0.17 0.03 2.9E-08 0.16 0.03 3.1E-08 
 
X rs146474788 A 0.14 0.94 0.17 0.03 2.9E-08 0.16 0.03 3.2E-08 
 
X rs149621038 T 0.16 0.94 0.16 0.03 4.0E-08 0.15 0.03 5.7E-08 
 
X rs138941436 G 0.15 0.94 0.16 0.03 5.7E-08 0.15 0.03 8.8E-08 
 
X rs185814586 G 0.13 0.90 0.17 0.03 6.1E-08 0.17 0.03 6.5E-08 
 
X rs1050828 T 0.14 0.98 0.16 0.03 9.1E-08 0.15 0.03 9.3E-08 
 
10 rs76969309 A 0.05 0.72 0.33 0.06 8.3E-08 0.32 0.06 7.6E-08 
 
Note: menopause status was only available on 2136/2347 JHS 
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Table 2.11 Replication of signals established in prior GWAS of iron measures including Subjects of European descent 
 
Trait 
 
Chr 
 
Index SNP Result in JHS a 
 
Most Significant SNP in JHS b 
 
Nearest Gene 
Index SNP EA EAF β SE P Most Significant SNP EA EAF β SE P LD r2  
 
TIBC 3 rs3811647*(20) A 0.22 17.55 1.43 9.7E-35 rs8177253 T 0.24 19.86 1.34 1.8E-47 1 TF 
TIBC 3 rs1830084(20) T 0.16 16.84 1.60 2.2E-25 rs1830084 T 0.16 16.84 1.60 2.2E-25 1 TF 
log_ferritin 6 rs17342717*(82) T 0.02 0.24 0.10 0.02 rs78273613* G 0.02 0.26 0.10 0.01 0.88 SLC17A1 
log_iron 6 rs1799945*(83) G 0.04 0.08 0.03 7.8E-04 rs129128 C 0.03 0.09 0.02 1.0E-04 0.92 HFE 
log_iron 6 rs1800562(20) A 0.01 -0.03 0.04 0.37 rs1800562 A 0.01 -0.03 0.04 0.37 1 HFE 
log_ferritin 6 rs1800562(82) A 0.01 0.20 0.10 0.05 rs1800562 A 0.01 0.20 0.10 0.05 1 HFE 
TIBC 6 rs1800562(20) A 0.01 -24.63 5.13 1.7E-06 rs1800562 A 0.01 -24.63 5.13 1.7E-06 1 HFE 
log_sat 6 rs1800562(20) A 0.01 0.05 0.04 0.14 rs1800562 A 0.01 0.05 0.04 0.14 1 HFE 
log_sat 6 rs13194491*(20) T 0.02 0.02 0.05 0.75 rs35657082* T 0.01 0.25 0.11 0.02 0.91 HIST1H2BJ 
log_iron 22 rs855791*(22) G 0.83 0.03 0.01 0.08 rs2072860* A 0.73 0.03 0.01 7.7E-03 0.90 TMPRSS6 
log_sat 22 rs855791*(22) G 0.83 0.02 0.01 0.15 rs4820268* A 0.73 0.02 0.01 0.03 0.90 TMPRSS6 
log_iron 22 rs4820268*(83) A 0.73 0.03 0.01 8.4E-03 rs9610638* C 0.80 0.05 0.02 3.5E-03 0.83 TMPRSS6 
* Imputed;  
( ) besides “Index SNP” contains the citation to the initial association study for each individual variant 
a
 Index SNP: Index SNP that was reported to be significantly (P<5x10
-8
) associated with iron-traits in prior GWAS in European 
descents 
b
 Most significant SNP: The proxy for index SNP (LD r
2
>0.8 in CEU 1000G with the index SNP) with the smallest association P 
value in JHS 
LD r
2
 : r
2
 with index SNP  in CEU 1000G subjects 
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(A) 
 
(B) 
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(C) 
 
(D) 
Figure 2.1 The LOD score of genome-wide admixture scan for iron-related phenotypes (A) 
TIBC, (B) log_ferritin, (C) log_iron, and (D) log_SAT. The LOD score is defined as the log 
base 10 ratio of the maximum likelihood of the data under a local-ancestry-associated disease 
model divided by the likelihood of the data under null model. Both alternative and null model 
include covariate adjustment for global ancestry. Positive LOD scores show the association of 
increased African ancestry with higher levels of iron measures, while negative LOD scores show 
the association of increased African ancestry with lower level of iron measures.  
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(A) 
 
(B) 
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(C) 
 
(D) 
Figure 2.2 Manhattan plot of the -log10(P) values by chromosome for iron-related 
phenotypes (A) TIBC, (B) log_ferritin, (C) log_iron, and (D) log_SAT. 
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(A)      (B) 
 
(C)       (D) 
Figure 2.3. Quantile-Quantile (Q-Q) plots of the P-values across all genotyped SNPs tested 
for association with iron-related phenotypes (A)TIBC, (B) log_ferritin, (C) log_iron, and (D) 
log_SAT in models adjusting for age, gender, BMI, and 10 eigenvectors calculated from 
principal component analysis.  Horizontal and vertical lines represent expected P values under 
null distribution and observed P values, respectively. The straight line represents the expected 
distribution assuming no inflation of the statistics.  
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Figure 2.4 Regional plot of the -log10(P) values for the SNPs in the TF region for TIBC 
before and after adjusting for the top SNP rs8177253 in this region (upper and lower 
panels, respectively). The X axis shows the human genome build 19 coordinates (Mb) and the 
genes in the region. The Y axis shows the -log10 association P values of SNPs on the left, and 
recombination rates in cM per Mb on the right. Different colors of shading indicate the strength 
of linkage disequilibrium (LD) (r
2
) between the top SNP and the other SNPs tested in the region. 
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Figure 2.5 Regional plot of the -log10(P) values for the SNPs at the HDGFL1 risk locus for 
TIBC. 
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Figure 2.6 Regional plot of the -log10(P) values for the SNPs at the MAF risk locus for TIBC.
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Figure 2.7 Regional plot of the -log10(P) values for the SNPs in the GAB3 region for 
log_ferritin. 
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CHAPTER III: GENOME-WIDE AND EXOME-WIDE ASSOCIATION STUDY OF 
SERUM LIPOPROTEIN (A) IN THE JACKSON HEART STUDY 
2
 
 
Introduction 
    Lipoprotein (a) [Lp(a)] is an independent risk factor for cardiovascular disease(27, 28). 
Genetic variants in LPA are strongly associated with both an increased level of Lp(a) and an 
increased risk of coronary disease(36), suggesting a causal role of Lp(a) in coronary disease. 
Lp(a) is a low-density lipoprotein (LDL)-like particle that consists of an apolipoprotein(a) 
covalently linked to apolipoprotein B100 by a disulfide bond(26).  Genetic factors have a large 
impact on the variation of Lp(a) levels and approximately 70-90% of the total variance of Lp(a) 
can be attributed to variation within the LPA locus across worldwide populations(34, 35). In LPA, 
a copy-number variation (CNV) which encodes a Kringle(IV) type 2 domain and accounts for 
approximately half of variance explained by LPA locus(37, 38). Recent genome-wide association 
studies (GWAS) in subjects of European descent have identified multiple polymorphisms 
spanning 12.5 Mb on chromosome 6q26-27, which includes LPA, that are significantly 
associated with Lp(a) levels independent of each other and of the Kringle IV size polymorphism 
in LPA (p<5x10
-8
)(37).  A candidate gene study on multi-ethnic populations suggested both 
SNPs at 6q26-27 and the Kringle IV CNV were genomic determinants of Lp(a) level, and the  
proportion of total variance explained by each determinant differ across ethnic groups(39). Lp(a) 
levels in populations of African ancestry are much higher (2~4-fold) than in populations of 
European ancestry(111). A genome-wide admixture study on a population of African American 
                                                 
2
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(AA) suggested local ancestry at 6q25.3 was significantly associated with Lp(a) after adjustment 
for the Kringle IV CNV(112). However, so far no genome-wide or exome-wide association 
studies of common and uncommon-coding variants, respectively, have been conducted in 
populations of African ancestry to assess the importance of other genomic regions on Lp(a) 
levels. 
Here we present a genome-wide and an exome-wide association study of Lp(a) among AAs 
participating in the Jackson Heart Study (JHS). We observed numerous SNPs at the well-
established LPA locus and a single SNP in APOE significantly associated with Lp(a) (p<5x10
-8
). 
A high burden of coding variants in LPA and APOE were also associated with higher Lp(a) 
levels.  
 
Materials and Methods 
Study subjects and phenotypes 
This study included 1106 AA male and 1789 AA female participants with measured Lp(a) levels 
and available genome-wide genotype data from the JHS, a longitudinal, population-based cohort 
from Jackson, MS(113). The design, recruitment and initial characterization of this study was 
described in details elsewhere(114). Serum Lp(a) levels (mg/dL) were measured using a Diasorin 
nephelometric assay on a Roche Cobas FARA analyzer (115). Fasting low-density lipoprotein 
(LDL), high-density lipoprotein (HDL), triglyceride (TG), and total cholesterol (TC) were 
measured as previously described(91). For each individual treated with lipid lowering therapies, 
the observed lipid value was multiplied by a correction factor (1.352 for LDL, 0.949 for HDL, 
1.210 for TG, and 1.271 for TC)(116). The study protocol was approved by the University of 
Mississippi Medical Center Institutional Review Board, and written informed consent was 
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obtained from all JHS participants. Descriptive characteristics of the JHS participants in this 
study were summarized in Table 3.1. 
 
Genome-Wide Genotype Data and Genotype Imputation 
A total of 3030 JHS participants were genotyped using the Affymetrix Genome-Wide Human 
SNP Array 6.0. Genotyping quality control was conducted using PLINK v1.07 (117). 874,712 
SNPs with a call rate greater than 0.95 and minor allele frequency (MAF) greater than 0.01 were 
included in the genotype imputation target panel. Thirty-eight million SNPs were imputed, using 
MACH 2.0 (118), based on a reference panel consisting of the complete sample of 1000 Genome 
Project participants (Nov 2010, Version 3); only SNPs with imputation quality of r
2
 greater than 
0.3 were included in further analysis. The Kringle IV CNV was not available in JHS participants. 
 
Exome Array 
A total of 2,790 JHS participants, including 2,448 with Affymetrix 6.0 genotype data, were 
genotyped using the Illumina Human Exome Beadchip (version 12v1_rev5), consisting 
of >200,000 putative functional variants selected from >12,000 individual exome and whole-
genome sequences across diverse populations and a range of common complex traits.  
 
Statistical analyses 
Association of local ancestry estimates  
Ethnic differences in Lp(a) levels have been observed between subjects of European and 
African descent, with some populations of African Americans having, on average, almost 4-fold 
higher Lp(a) levels than European Americans(111). To assess the impact of genetic admixture 
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within our AA population on Lp(a) levels, we first estimated the average, or global, African 
ancestry proportion across the genome for all subjects using the software ADMIXTURE (119) 
assuming K=2 contributing populations. We then tested whether this estimated proportion was 
associated with natural-log-transformed Lp(a) levels after adjusting for age, sex, and body mass 
index (BMI).  Next, ANCESTRYMAP (72)
 
was used to estimate local ancestry (probabilities of 
whether an individual has 0, 1, or 2 alleles of Caucasian ancestry) at 738,831 autosomal SNPs 
across the genome for each participant in JHS as previously described (91).  In brief, local 
ancestry was inferred using hidden Markov models based on the genotypes from a panel of 
densely spaced markers with highly differential allele frequencies between African and European 
populations. We performed admixture mapping across the whole genome by regressing natural-
log-transformed Lp(a) levels, adjusting for age, sex, BMI and global ancestry, on the local 
ancestry estimate at each SNP location. The LOD score for association, defined as the log-base-
10 ratio of the likelihood of the data under a model including local ancestry divided by the 
likelihood of the data under the model excluding local ancestry, was computed at each of these 
local ancestry informative marker locations across the genome. For regions showing association 
of increased African ancestry with higher levels of Lp(a), the LOD scores were assigned positive 
values, and for regions showing association of increased African ancestry with lower levels of 
Lp(a), the LOD scores were assigned negative values. LOD scores were plotted across the whole 
genome, and a LOD score of 5 was assumed to be the threshold of statistical significance(72). 
 
Genome-wide association analysis 
Lp(a) levels were natural log-transformed to approximate normality of residuals after accounting 
for age, sex and BMI. The association between Lp(a) and imputed SNPs were tested using 
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112.w1qqmultivariable linear regression models in MACH2QTL v.1.08 (118), adjusting for age, 
sex, BMI and the first 10 principal components generated from EIGENSOFT (120) based on a 
linkage disequilibrium pruned set of SNPs with minor allele frequency (MAF) > 0.05. An 
additive mode-of-inheritance model was assumed for genotype;  coefficients, representing the 
estimated change in transformed trait value associated with each additional copy of the effect 
allele, and there corresponding standard errors were reported 
Manhattan plots were made to illustrate the association results across the genome. 
Quantile-quantile (Q-Q) plots of observed versus expected -log10(P-values) were made to assess 
any systematic inflation of the regression test statistics across the genome before and after 
removing the SNPs in the 6q25.3 region widely reported to be significantly associated with Lp(a). 
The genomic inflation factor (λ), defined as observed median value of the chi-squared statistic 
divided by 0.456, was calculated excluding 6q25.3 SNP results.  The observed chi-square 
statistics were divided by λ to obtain the corrected chi-square statistics and corrected p-values. In 
regions with significant evidence for association, multivariable “conditional” regression models 
that included the imputed genotype data of the most strongly associated SNP as an additional 
covariate were performed to assess the evidence for multiple independently associated SNPs in 
the region. If a second signal also reached genome-wide significance after conditioning on the 
top variant, multivariable regression models were repeated to include the genotypes of both 
SNPs as covariates. Region-specific plots were made to show the magnitude of association 
between all SNPs and Lp(a) levels as well as the estimated linkage disequilibrium (LD) between 
each SNP in the region and the most strongly associated SNP. Finally, in order to control our 
association results for possible confounding due to ancestry, for any observed associated SNP we 
identified the genetic position of the most strongly associated SNP in the associated region, 
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selected the local ancestry estimate at the location closest to that SNP, and performed 
multivariable regression models as described above but now including estimated local ancestry 
proportion as an additional covariate.  
 
Identifying the most important 6q associated SNPs using LASSO-based resample model 
averaging 
 
          In order to identify the SNPs that most likely contribute to the observed association at 6q, 
we applied the LASSO local automatic regularization resample model averaging (LLARRMA) 
method, a method that combines LASSO variable shrinkage and selection with resample model 
averaging and multiple imputation (121), to estimate the probability of each SNP to be included 
in a multi-SNP model that best explains the Lp(a) outcome across alternative realizations of the 
data. We first extracted the genotypes for SNPs on the Affy 6.0 array that mapped within the 1 
Mb region centered around the top genotyped SNP (rs9457986) identified in the initial GWAS 
scan. Then we used fastPHASE (122) to impute the missing genotypes for SNPs in this region 
which failed genotyping on Affy 6.0. Finally, we fitted the LASSO models by regressing the 
residuals of Lp(a) adjusting for age, gender, BMI, 10 principle components and the local 
ancestry estimate of rs9457986 on the genotypes using the LLARRMA package in R, and 
calculated a resample model inclusion probability (RMIP) score for each SNP in this 1Mb region 
on chromosome 6. Linkage disequilibrium (LD) statistics (R
2
 and D’ based on 1000G YRI 
subjects) between variants with RMIP >0.75 were calculated using Gold(123) and plotted using 
Haploview(124).  
Haplotype analyses 
Haplotype analyses were conducted using the ‘haplo.stats’ R package(125), to examine 
specific combinations of allelic variants and whether the observed association signal is likely 
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attributable to a less common unmeasured genetic variant. Haplotypes were constructed among 
the five genotyped variants in the LPA gene with RMIP score >0.75. The ‘haplo.glm’ function 
implemented in the ‘haplo.stats’ R package was used to calculate effect coefficients (β), standard 
errors (SE) and P-values for each haplotype relative to the most common reference haplotype. 
The ‘haplo.score’ function was used to calculate the global score statistic to test the overall 
association between haplotypes and log-transformed Lp(a). The same set of covariates used in 
the genotype analyses were used in the haplotype analyses. 
Single variant and gene-based analysis of SNPs on  Exome Array 
Single variant and multivariant, gene-set or “gene-burden”, association analyses were performed 
for variants appearing on the Exome Array. Gene-burden tests performed included the Madsen-
Browning test(126) and the SKAT-Optimal (127) test, which picks the ‘best’ combination of the 
SKAT(128) and a Madsen-Browning(126) test for gene-based testing. We performed three levels 
of gene-based analyses: (Level 1) the combination of stop-loss, stop-gain, and splice-site 
regardless of MAF; (Level 2) the combination of SNPs in Level 1 and all variants which are 
predicted to be “damaging” using PolyPhen(129) and SIFT(130) regardless of MAF; (Level 3) 
the combination of stop-loss, stop-gain, splice-site and non-synonymous variants with MAF 
upper limits of 3%.  
To investigate how much common or rare SNPs associated with Lp(a) in the single-variant 
analysis could account for gene-based test, conditional analysis was performed by including the 
allele count at these lead SNPs as covariates. In order to control for the possible confounding of 
Lp(a) association results due to an association between both SNP and Lp(a) with other lipid traits 
(HDL, LDL, TG and TC), we performed general linear mixed model regression as described 
above but now including the lipid traits an additional covariate.  
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Statistical significance 
A significance threshold of P <5×10
−8
 was used to define genome-wide significance for all 
individual SNP results (both GWAS and Exome Array).  Test statistics for all individual SNP 
results, both GWAS and Exome-Chip, were adjusted by the genome inflation factor (λ) prior to 
calculating significance (p-values) to account for any possible systematic bias in results. A gene-
based association result was defined to be significant if P<0.05/number of genes. The number of 
genes for Level 1, Level 2, and Level 3 inclusion criteria were 4752, 13658, and 15963, resulting 
in significance thresholds of 1.1 x10
-5
, 3.7x10
-6
, and 3.1x10
-6
, respectively.   
 
Results 
      Descriptive statistics of the JHS participants in this study were summarized in Table 3.1. 
Admixture mapping for determinants of Lp(a)  
Consistent with observed higher levels of Lp(a) in AAs versus EAs, higher levels of 
estimated global, or average, African ancestry was significantly associated with higher levels of 
log-transformed Lp(a) (β=0.76, p=1.3x10-9). The estimated global proportion of African ancestry 
obtained from ADMIXTURE was highly correlated with the first principal component from 
EIGENSTRAT (correlation=0.998). Admixture mapping showed a highly significant association 
between increased African ancestry at chromosome 6q25.3 and increased Lp(a) levels (Figure 
3.1) after adjusting for the global proportion of African ancestry. The estimated global 
proportion of African ancestry became non-significant after including local ancestry at 6q25.3. 
SNP rs505000, upstream of SLC22A3 was the local ancestry informative SNP most strongly 
associated with Lp(a) levels (p= 8.2x10
-27
, LOD=24.95).   
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GWAS SNPs associated with Lp(a) at P<5x10
-8
 
Q-Q plots revealed evidence for systematic inflated association results likely due to left-
censoring of the Lp(a) measures in a subset of JHS participants. After excluding all the SNPs on 
chromosome 6, the distribution of the remaining P values across the genome still demonstrated 
inflation. After controlling for the genomic inflation factor (λ=1.14), Q-Q plots revealed no 
substantial evidence for inflation (Figure 3.2). The genomic inflation factor was applied to all 
individual SNP results. Only chromosome 6q region reached genome-wide significance for Lp(a) 
levels (Figure 3.3) after adjusting for the inflation factor. Overall, 804 SNPs reached genome-
wide significance (p<5x10
-8
) (all on chromosome 6), and the top SNPs that reached genome-
wide significance are listed in Table 3.2.  
Lp(a) GWAS Results on Chromosome 6 
All 804 significant SNPs on chromosome 6 mapped to the 6q region, spanning from 153,917,144 
to 163,745,411bp and containing more than 10 genes (Figure 3.4). The strongest signal 
(rs115848955, p=3.1x10
-55
, MAF=0.05) mapped to the LPA gene. LPA gene encodes a modified 
form of low density lipoprotein, in which a large glycoprotein (Apo(a)) is covalently bound to 
apolipoprotein B by a disulfide bridge(131), and structurally, the Apo(a) chain contains a region 
homologous with plasminogen, which gives Lp(a) anti-fibrinolysis activity by competing with 
plasminogen’s binding to fibrin. After adjusting for the top SNP (rs115848955), the top 
associated variant was rs9355814 (p=7.8x10
-21
) (Figure 3.4) and 469 SNPs in the 6q region 
spanning from 159,092,125- 163,745,411 bp remained genome-wide significant. However, after 
adjusting for the local ancestry informative marker closest to rs115848955 (i.e. rs6923917), only 
406 SNPs in a relatively narrow region spanning from 160,633,560 to 161,342,219 bp remained 
significant (p<5x10
-8
). The top SNP in the conditional analysis including local ancestry was 
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rs138429428 (p=4.2x10
-50
, Figure 3.4). The local ancestry estimate closest to rs115848955 
explained an estimated 4.4% of the total variation of Lp(a) after accounting for age, gender, BMI 
and the first 10 PCs. SNP rs115848955 explained an estimated 8.8% of the total variation of 
Lp(a) after accounting for age, gender, BMI, the first 10 PCs, and the local ancestry estimate 
nearest this location. 
Evidence for multiple associated SNPs in the LPA region on chromosome 6  
Fifteen directly genotyped SNPs in the 1Mb region surrounding the top associated SNP 
(rs9457986) on chromosome 6 were identified as having stable, independent associations with 
Lp(a) (RMIP score >0.75) in multivariant models using LLARRMA, as shown in Table 3.3. The 
LD estimates between these SNPs were not high, as shown in Figure 3.5. Five of the SNPs 
(rs6415084 [RMIP=0.93], rs3798221 [RMIP=1], rs9457986 [RMIP=1], rs1367211 [RMIP=0.97], 
and rs1406888 [RMIP=1]) were in the LPA gene. The five Lp(a) SNPs together explained an 
estimated 7.3% of the total variance of Lp(a) after accounting for age, gender, BMI, the first 10 
PCs, and local ancestry estimate at rs9457986. These 5 SNPs were used to construct haplotypes 
and to estimate the effect on Lp(a) levels for each additional copy of a particular haplotype, 
compared to the reference haplotype (Table 3.4). There was significant evidence for an overall 
association between haplotypes and Lp(a) (global P=1.12x10
-55
) ; 6 individual haplotypes were 
minimally nominally associated (p < 0.05) with Lp(a) levels. 
Single variant and gene-based analysis for Exome Array 
Seven SNPs on the Exome Array were associated (p<5x10
-8
) with Lp(a) (Table 3.5) after 
adjustment for the genomic inflation factor, six of them were in the chromosome 6q LPA region, 
and the other was the widely reported chromosome 19 APOE SNP rs7412. Five of the six 
associated chromosome 6q SNPs remained genome-wide significant after adjusting for top 
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GWAS SNP rs115848955 (Table 3.5). Five of the six SNPs (excepting rs41272114) were 
intronic or in intergenic regions. Of the seven SNPs, only rs7412 was not significant in the 
1000G imputed GWAS results. Rs7412 (p=3.3x10
-8
) was poorly imputed based on 1000G data 
and was not included in the original GWAS analyses. In the gene-based analyses, the LPA gene 
reached exome-wide significance for all three levels of SNP inclusion when using the Madsen-
Browning test, as well as for Level 2 and Level 3 SNPs in the SKAT-O test. The APOE gene 
reached exome-wide significance for Level 2 SNPs using the Madsen-Browning test (Table 3.6).  
Uncommon functional variants in LPA and APOE 
All splice-site, stop altering and non-synonymous SNPs in LPA and APOE on the Exome Array 
are listed in Table 3.7 and Table 3.8, respectively. The most significant individual SNP in LPA 
on the Exome Array was rs41272114 (p=6.5x10
-12
, MAF=0.01), which is a splicing-altering 
variant. LPA SNPs were significantly associated with Lp(a) levels in the gene-burden tests 
(p=1.2x10
-21
 for Level 3 SNPs using Madsen-Browning test). The Level 3 gene-based Madsen-
Browning test remained significant after removing the top two individual SNP results (i.e. 
rs41272114 and rs41272110) (Table 3.9). Only three APOE SNPs, including the aforementioned 
rs7412, were successfully genotyped and informative on the Exome Array. A second 
nonsynonymous APOE SNP (rs769455, MAF=0.02) that is specific to populations of African 
descent, demonstrated strong nominal results that were independent of rs7412 (p=2.0x10
-5
 before 
adjustment for rs7412 and p = 3.5x10
-5
after adjustment for rs7412). Together, rs7412 and 
rs769455 explain ~2.3% of the total variation of Lp(a) after adjusting for age, gender, BMI and 
the first 10 PCs. 
 Since APOE is a strong risk factor for lipid traits (LDL and TC), we next investigated 
whether the association between APOE and Lp(a) is attenuated when adjusting for lipid traits. 
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We re-tested the association between signal at APOE and Lp(a) adjusting for the untreated LDL 
and TC levels, and found that the evidence for association decreased, but the signal did not 
totally disappear (Table 3.8, P value for rs7412  dropped from 3.2x10
-8
 to 7.6x10
-4
).  
 
Discussion 
We conducted genome-wide and exome-wide association studies for Lp(a) in 2,896 AA 
participating in the Jackson Heart Study. Higher level of estimated global African ancestry was 
significantly associated with higher level of Lp(a), and this association of global ancestry was 
largely explained by the association between Lp(a) and local ancestry in the chromosome 6q25.3 
region. We observed significant (P<5x10
-8
) associations for hundreds of SNPs spanning ~10Mb 
region on 6q surrounding the LPA gene. Interestingly, after adjusting for local ancestry, the 
region containing significantly associated SNPs got much narrower and was centered over the 
LPA gene (<1Mb). Significant haplotypic effects were also detected in the LPA region that 
implicates numerous causal variants. A single APOE SNP, rs7412 on the Exome Array also 
reached genome-wide significance. Gene-burden tests found significant associations between 
Lp(a) and aggregate collections of SNPs in LPA and APOE. 
     Previously, Deo et al. performed a targeted study of the Lp(a) region, using haplotype tagging 
SNPs, in 4,464 JHS participants and 1,726 AA participants from the Dallas Heart Study.
11
  This 
study also performed a genome-wide admixture analyses based on a panel of 1,447 ancestry 
informative markers including subjects in the upper and lower quintile of the Lp(a) distribution.  
Herein, we dramatically expand the coverage of both common and rare variants across the entire 
LPA region; estimate local genetic admixture at 738,831 autosomal SNP locations and perform 
admixture mapping including all subjects with Lp(a) measures.  Eight-hundred-four SNPs in the 
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6q region (spanning ~10 Mb) were significantly associated with Lp(a) levels (P<5x10
-8
). After 
adjusting for the most strongly associated SNP rs115848955, multiple signals at 6q region 
spanning ~5 Mb remained significantly associated with Lp(a).  After adjusting for the local 
ancestry at 6q25.3, the region that harbors SNPs significantly associated with Lp(a) (p<5x10
-8
) 
became much narrower (from 9.8Mb to 0.7Mb) and was centered around the three genes 
SLC22A, LPL2 and LPA. This result suggests confounding between local ancestry and SNPs 
spanning the larger 6q region identified to be associated with Lp(a). Given the relatively recent 
admixture in the African American population, local ancestry can confound associations across a 
relatively large region surrounding the population-specific, or population-enriched, causal 
variant(s)(132, 133). The observation that the associations in and near LPA remains robust after 
adjustment for local ancestry at LPA while the evidence for association further away 
dramatically declines suggests that the ancestry-specific (or highly-enriched) causal risk variant(s) 
resides in or near LPA and that most, if not all, of the observed associations outside this narrower 
region are spurious associations. Interestingly, a similar extended region of association with Lp(a) 
surrounding LPA has been observed in more homogeneous European populations. An obvious 
candidate to explain some of the differences in association results between European and African 
populations is the Kringle IV polymorphism, which has not been measured in JHS participants. 
Deo et al. demonstrated that the Kringle IV polymorphism explains some of the ancestry effect 
differences, but noted that several associated common SNPs, with strong allele frequency 
differences between populations of African and European ancestry, in and around LPA explain 
the majority of the population differences in Lp(a) levels.
11
 
 A common non-synonymous variant at APOE on Exome Array, rs7412, was identified to 
be significantly associated with Lp(a) in single variant analysis (MAF=0.11, leading to an Arg to 
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Cyc substitution, p=3.2x10
-8
). Another low-frequency non-synonymous variant at APOE, 
rs769455, was also nominally associated with Lp(a) (MAF=0.02, leading to an Arg to Cyc 
substitution, p=2.0x10
-5
). Prior studies have investigated the relationship between APOE 
genotypes and Lp(a) levels, but the results were inconsistent. Some studies reported no impact of 
APOE genotypes on Lp(a) levels(134-138), while others reported significant associations 
between them(139-144). A recent study found that among African Americans, lower Lp(a) levels 
were observed in APOE ε2 carriers, and this association was only observed in subjects with large 
apoA size (defined as >26 Kringle IV repeats) but not in the subjects with small apoA size(145). 
Another study on Caucasian males also reported that the effect of APOE on Lp(a) levels was 
only observed in subjects of largest quartile of apoA size, but with lower Lp(a) levels for APOE 
ɛ4 carriers(141). In our study, APOE ε2 genotype was associated with lower Lp(a) levels, which 
is consistent with prior study on African Americans. 
In summary, we observed that local ancestry at 6q25.3 was an important risk factor for Lp(a) 
in AA, and that SNPs at the well-established LPA locus were significantly associated with Lp(a) 
(p<5x10
-8
) after adjusting for the local ancestry at 6q25.3. Prior to covariate adjustment for local 
ancestry at 6q25.3, the observed region containing associated SNPs spanned ~10 Mb. After 
covariate adjustment the associated region was only 700 kb. We also observed a significant 
association for a non-synonymous variant in APOE. Future large multi-ethnic studies which 
include high-coverage sequence data, and the Kringle IV polymorphism, would be ideally suited 
to better understand the complex genetic architecture of the LPA region that leads to strong 
population differences in Lp(a) levels. 
 
 
 69 
 
Conflicts of Interest 
The authors declare no conflict of interests. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 70 
 
Table 3.1 Descriptive statistics of JHS participants for the study of Lp(a) 
 Total Male female 
N 2896 1107 1789 
Age(years) 54.4 ± 12.9 53.8 ± 13.0 54.8 ± 12.8 
BMI 32.1 ± 7.5 30.0 ± 6.3 33.3 ± 7.9 
Lp(a) (mg/dL) 47 (25, 80) 42 (23,74) 50 (26, 84) 
LDL-c (mg/dL)
1
 128 (103, 153) 130 (106, 155) 127 (101, 151) 
HDL-c (mg/dL)
2
 49 (40, 59) 43 (37, 51) 52 (44, 62) 
TG (mg/dL)
3
 93 (66, 131) 98 (70, 139) 89 (62, 125) 
TC (mg/dL)
4
 199 (175, 229) 198 (175, 228) 200 (175, 230) 
 
Note:  
Data are mean ± SE, median (25th, 75th percentiles); lipid levels are untreated;  
1: LDL-c, low-density lipoprotein cholesterol;  
2: HDL-c, high-density lipoprotein cholesterol; 
3: TG, triglycerides; 
4: TC, total cholesterol 
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Table 3.2 Top SNPs that significantly (p<5x10
-8
) associated with Lp(a) after controlling for genomic inflation factor 
1: Chr, chromosome ;2: # of SNPs, number of SNPs that reached genome-wide significance at each locus;  3: Pos(hg19), physical 
position of the SNP according to human genome build version 19; 
4: EA, effect allele;  5: EAF, effect allele frequency; 6: RSQR, RSQR represents the imputation quality provided by MACH. SNPs 
with RSQR<0.3 were excluded from analyses;  
7: β, β coefficients representing the estimated change in the log-Lp(a) level associated with each additional copy of the effect allele;  8: 
SE, standard error; 9: P, p-value after genomic control 
Models were adjusted for age, gender, BMI, and 10 PCs. 
 
Chr1 # of 
SNPs2 
Most significant SNP Pos(hg19)3 EA4 EAF5 RSQR6 β7 SE8 P1 Nearest Gene Function 
6 5 rs9322428 153917946 A 0.85 0.95 0.19 0.03 1.3E-09 RGS17-OPRM1 intergenic 
6 6 rs17539620 154896235 T 0.05 0.85 -0.33 0.05 3.7E-10 CNKSR3-SCAF8-TIAM2 intergenic 
6 24 6:156789295:T_TAC 156789295 I 0.16 0.74 -0.22 0.03 4.7E-11 NOX3-ARID1B intergenic 
6 5 rs6909229 158572379 C 0.07 0.92 -0.27 0.04 3.7E-10 SYNJ2-SERAC1-GTF2H5-TULP4 intronic 
6 19 6:159106232:G_GTC 159106232 I 0.60 0.95 0.18 0.02 4.8E-15 SYTL3 intronic 
6 41 rs926657 159463452 T 0.42 0.99 0.14 0.02 4.6E-11 C6orf99-RSPH3-TAGAP-FNDC1-SOD2-PNLDC1-MAS1-
IGF2R 
intergenic 
6 261 rs149565105 160878078 A 0.02 0.97 0.78 0.06 1.7E-34 SLC22A1-SLC22A2-SLC22A3 intronic 
6 55 rs185414370 160889898 C 0.03 0.92 0.82 0.06 2.9E-40 LPL2 ncRNA_intronic 
6 177 rs115848955 161031660 T 0.05 0.90 0.79 0.05 1.3E-62 LPA intronic 
6 130 rs144788267 161181875 A 0.03 0.75 0.83 0.07 4.6E-30 PLG intergenic 
6 25 rs142799378 161305763 G 0.02 0.85 0.81 0.08 6.8E-23 MAP3K4 intergenic 
6 24 rs3757037 161697400 G 0.66 0.68 0.20 0.03 3.3E-13 AGPAT4 intergenic 
6 27 rs7769089 162147727 T 0.67 1.00 0.16 0.02 4.6E-12 PARK2 intronic 
6 5 rs6927207 163740089 A 0.22 0.75 -0.19 0.03 1.3E-11 PACRG-AS1 ncRNA_intronic 
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Table 3.3 LD statistics of 15 SNPs in the 1Mb hit region on chromosome 6 with RMIP>0.75 for Lp(a) 
Gene RMIP score SNP rs7757997 rs3850659 rs377551 rs2457576 rs7754188 rs6415084 rs3798221 rs9457986 rs1367211 rs1406888 rs9458005 rs783147 rs1406891 rs1247568 rs1247340 
SLC22A2 0.78 rs7757997 1.00 0.36 0.07 0.00 0.02 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 
SLC22A2 1 rs3850659 0.63 1.00 0.07 0.01 0.06 0.00 0.00 0.02 0.04 0.01 0.02 0.01 0.00 0.00 0.00 
SLC22A3 1 rs377551 0.58 0.55 1.00 0.17 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
SLC22A3 0.95 rs2457576 0.04 0.25 0.78 1.00 0.03 0.00 0.00 0.03 0.04 0.01 0.00 0.02 0.01 0.00 0.00 
LPAL2 0.98 rs7754188 0.21 0.32 0.06 0.47 1.00 0.00 0.05 0.02 0.03 0.00 0.01 0.01 0.00 0.00 0.00 
LPA 0.93 rs6415084 0.07 0.05 0.07 0.11 0.02 1.00 0.11 0.25 0.00 0.11 0.02 0.00 0.00 0.00 0.01 
LPA 1 rs3798221 0.01 0.23 0.11 0.05 0.36 0.99 1.00 0.03 0.00 0.00 0.02 0.04 0.00 0.00 0.00 
LPA 1 rs9457986 0.05 0.15 0.08 0.74 0.18 0.91 0.94 1.00 0.23 0.01 0.06 0.01 0.00 0.00 0.00 
LPA 0.97 rs1367211 0.23 0.39 0.02 0.39 0.27 0.04 0.10 1.00 1.00 0.20 0.01 0.07 0.01 0.00 0.00 
LPA 1 rs1406888 0.06 0.25 0.03 0.14 0.12 0.39 0.08 0.24 0.66 1.00 0.00 0.11 0.01 0.00 0.01 
PLG 0.89 rs9458005 0.11 0.13 0.12 0.17 0.10 0.22 0.62 0.26 0.24 0.02 1.00 0.00 0.00 0.01 0.00 
PLG 0.86 rs783147 0.27 0.43 0.04 0.13 0.21 0.00 0.25 0.47 0.51 0.44 0.23 1.00 0.01 0.06 0.00 
PLG 0.86 rs1406891 0.03 0.01 0.06 0.15 0.03 0.00 0.11 0.00 0.13 0.09 0.03 0.17 1.00 0.06 0.00 
PLG 0.98 rs1247568 0.04 0.03 0.04 0.17 0.03 0.01 0.21 0.06 0.01 0.10 0.08 0.82 0.32 1.00 0.00 
PLG 0.93 rs1247340 0.08 0.07 0.04 0.06 0.05 0.11 0.07 0.08 0.06 0.13 0.07 0.12 0.03 0.05 1.00 
 
Note: 
The lower left part showed the D’ and the upper right part showed the R2; 
RMIP score:  resample model inclusion probability score. 
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Table 3.4 Lp(a) association with haplotypes consisting of SNPs on LPA gene reprioritized 
by LLARRMMA 
 
Haplotype rs6415084 rs3798221 rs9457986 rs1367211 rs1406888 Freq β SE P 
A T G T T T 0.04 0.86 0.06 2.7E-45 
B T G T T C 0.12 0.27 0.04 1.2E-11 
C T G C T C 0.02 -0.12 0.07 0.10 
D T G C C T 0.17 0.17 0.04 1.2E-06 
E T G C C C 0.05 0.07 0.06 0.20 
F C T C T C 0.07 0.03 0.05 0.54 
G C T C C T 0.05 -0.17 0.05 1.7E-03 
H C G C T C 0.20 0.20 0.03 1.3E-09 
I C G C C T 0.06 0.23 0.06 7.0E-05 
Rare * * * * * 0.04 -0.05 0.07 0.45 
Base C G C C C 0.17    
 
Global score= 303.3, df=15, global p-value=1.1E-55 
Freq: Haplotype frequency  
Effect size(β), standard errors (SE), and P values were calculated for each haplotype compared 
with the reference haplotype.  
Significant associations (P<0.05) are in boldface. 
Models were adjusted for age, gender, BMI, 10 PCs, and local ancestry estimate at the top SNP 
rs9457986.  
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Table 3.5 SNPs on Exome-chip that significantly (p<5x10
-8
) associated with Lp(a) after controlling for genomic inflation factor 
Notes: 
1: Chr, chromosome; 2: Pos(hg19), physical position of the SNP according to human genome build version 19; 3: MAF, minor allele 
frequency; 
4: β, β coefficients representing the estimated change in the log-Lp(a) level associated with each additional copy of the minor allele;  
5: SE, standard error; 6: P, p-value after genomic control;  
7: β.adj, SE.adj, and P.adj were reported after adjusting for the lead SNP from GWAS signal, rs115848955; 
8: RSQR.in.GWAS, the imputation quality of the Exome-chip SNP in GWAS 1000G; 9: P.in.GWAS, the p-value after genomic 
control in GWAS; 
Models were adjusted for age, gender, BMI, and 10 PCs. 
 
 
 
 
         after adjusting for rs115848955   
Chr1 Gene Function SNP Pos(hg19)2 MAF3 β4 SE5 P6 β.adj7 SE.adj7 P.adj7 RSQR.in.GWAS8 P.in.GWAS9 
6 MIR1202-ARID1B intergenic rs9478712 156858484 0.14 -0.23 0.03 7.7E-11 -0.20 0.03 6.4E-09 0.99 1.3E-08 
6 SYTL3 intronic rs894124 159096121 0.39 -0.15 0.02 8.8E-10 -0.14 0.02 3.1E-09 0.99 7.1E-12 
6 LPA intronic rs6919346 160960359 0.03 -0.43 0.07 1.5E-09 -0.39 0.06 6.0E-09 0.99 2.1E-09 
6 LPA splicing rs41272114 161006077 0.01 -0.80 0.11 6.5E-12 -0.72 0.11 8.8E-11 0.55 3.2E-11 
6 LPA intronic rs1652507 161082461 0.08 -0.36 0.04 4.4E-16 -0.30 0.04 2.6E-12 0.99 6.3E-19 
6 PARK2 intronic rs6455767 162148335 0.28 -0.15 0.03 1.4E-08 -0.12 0.03 1.7E-06 0.94 5.2E-10 
19 APOE exonic;nonsynonymous rs7412 45412079 0.11 -0.21 0.04 3.3E-08 -0.21 0.04 3.3E-08 0.28 3.3E-03 
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Table 3.6 Genes on Exome-chip associated with Lp(a) in gene-based analysis  
 Madsen-Browning test  SKAT-O test 
 Gene P β SE cmafTotal1 cmafUsed2  Gene P cmafUsed2 # of SNPs 
level 1 LPA 7.4E-14 -0.76 0.10 0.01 0.01      
level 2 LPA 1.5E-13 -0.44 0.06 0.04 0.04  LPA 1.0E-06 0.04 14 
 APOE 1.1E-12 -0.24 0.03 0.13 0.13      
level 3 LPA 1.2E-21 -0.40 0.04 0.55 0.08  LPA 6.2E-17 0.08 24 
Note:  
Lp(a) levels were log transformed and residuals were adjusted for age, gender, BMI, 10 PCs, and family relatedness; 
Gene-based tests were carried out using Madsen-Browning test and SKAT-O test respectively; 
level 1 is the combination of stop-loss, stop-gain, and splice-site regardless of MAF; 
level 2 is the combination of SNPs in level 1 and all variants which are predicted to be “damaging” using PolyPhen regardless of MAF; 
level 3 is the combination of stop-loss, stop-gain, splice-site and non-synonymous variants with MAF upper limits of 3%; 
A gene-based association was defined to be significant if P<0.05/number of genes; 
Number of genes for level 1, level 2, and level 3 were 4752, 13658, and 15963, corresponding to a p value of 1.05 x10
-5
, 3.66x10
-6
, 
and 3.13x10
-6
;   
1: cmafTotal, cumulative MAF of total Exome-chip variants in the LPA gene; 
2: cmafUsed, cumulative MAF of Exome-chip variants in the LPA gene that were included in the  gene-based test. 
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Table 3.7 All stop-altering, splice-site and non-synonymous variants at LPA region 
 
SNP Pos(hg19) Gene MAF A1 A2 β SE Function LOF (level 1) Damaging (level 
2) 
P 
rs186413938 160952780 LPA 8.53E-04 T C -0.28 0.40 exonic;nonsynonymous FALSE FALSE 0.50 
rs41267807 160952816 LPA 1.49E-03 C T -0.34 0.30 exonic;nonsynonymous FALSE TRUE 0.29 
rs41267809 160953642 LPA 3.62E-03 G A -0.60 0.19 exonic;nonsynonymous FALSE FALSE 3.01E-03 
rs3798220 160961137 LPA 8.53E-03 C T 0.23 0.12 exonic;nonsynonymous FALSE TRUE 0.08 
rs139145675 160966559 LPA 9.81E-03 A G -0.47 0.12 exonic;nonsynonymous FALSE TRUE 1.35E-04 
rs144281871 160968889 LPA 5.12E-03 A C -0.02 0.16 exonic;nonsynonymous FALSE FALSE 0.89 
rs143431368 160969693 LPA 8.53E-04 C T -1.24 0.39 splicing TRUE TRUE 2.21E-03 
rs200099994 160998167 LPA 2.13E-04 T C -1.48 0.80 splicing TRUE TRUE 0.07 
rs41267813 160998199 LPA 4.26E-04 A G -1.41 0.57 exonic;nonsynonymous FALSE TRUE 1.64E-02 
rs140720828 160998277 LPA 1.71E-03 A G -0.67 0.28 exonic;nonsynonymous FALSE TRUE 2.11E-02 
rs41272114 161006077 LPA 1.07E-02 T C -0.80 0.11 splicing TRUE TRUE 6.52E-12 
rs76144756 161006084 LPA 8.53E-04 A G -0.90 0.43 exonic;nonsynonymous FALSE FALSE 4.25E-02 
rs41272112 161006105 LPA 0.05 T C -0.12 0.05 exonic;nonsynonymous FALSE FALSE 2.82E-02 
rs41272110 161006172 LPA 2.62E-02 G T -0.35 0.07 exonic;nonsynonymous FALSE FALSE 2.36E-06 
rs7765781 161007496 LPA 0.42 G C -0.08 0.02 exonic;nonsynonymous FALSE FALSE 8.88E-04 
rs41267817 161010615 LPA 2.13E-04 C T -0.62 0.80 exonic;nonsynonymous FALSE FALSE 0.45 
rs41267819 161011993 LPA 2.13E-04 A G -1.90 0.80 exonic;nonsynonymous FALSE FALSE 2.17E-02 
rs200561706 161015041 LPA 4.90E-03 A G -0.59 0.16 exonic;nonsynonymous FALSE TRUE 6.01E-04 
rs142720914 161016427 LPA 2.13E-04 A G 0.94 0.74 exonic;nonsynonymous FALSE TRUE 0.22 
rs199952286 161020632 LPA 4.26E-04 A G 0.10 0.57 exonic;stopgain TRUE TRUE 0.87 
rs113020022 161020641 LPA 6.40E-04 T G -0.37 0.46 exonic;nonsynonymous FALSE FALSE 0.44 
rs41259144 161022107 LPA 1.07E-03 T C 0.46 0.35 exonic;nonsynonymous FALSE TRUE 0.21 
rs201480327 161026077 LPA 4.26E-04 T C -0.06 0.49 splicing TRUE TRUE 0.91 
rs139937718 161026078 LPA 4.26E-04 A G 0.03 0.57 exonic;splicing;nonsynonymous TRUE TRUE 0.96 
rs200802664 161027512 LPA 6.40E-04 C G -0.68 0.46 exonic;nonsynonymous FALSE FALSE 0.16 
rs200163192 161027551 LPA 6.41E-04 A T -0.26 0.45 exonic;nonsynonymous FALSE FALSE 0.57 
LOF: loss of function, including stop-loss, stop-gain, and splice-site regardless of MAF; level 1 of gene-based analysis include SNPs 
with LOF=TRUE. 
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Damaging: LOF variants plus non-synonymous variants which are predicted to be “damaging” using PolyPhen; Level 2 of gene-based 
analysis include SNPs with damaging=TRUE 
P: p-value after genomic control 
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Table 3.8 All stop-altering, splice-site and non-synonymous variants at APOE region  
           after adjusting for LDL after adjusting for log_TC 
SNP Gene Pos (hg19) Function amino acid MAF A1 A2 β SE P β SE P β SE P 
rs7412 APOE 45412079 exonic;nonsynonymous R>C 0.11 T C -0.21 0.04 3.2E-08 -0.13 0.04 7.6E-04 -0.15 0.04 2.0 E-04 
rs769455 APOE 45412040 exonic;nonsynonymous R>C 0.021 T C -0.36 0.08 2.0E-05 -0.27 0.08 1.0E-03 -0.31 0.08 2.3E-04 
chr19:45412056 APOE 45412056 exonic;nonsynonymous R>H 6.4E-04 A G 0.09 0.42 0.84 0.33 0.44 0.48 0.30 0.45 0.52 
P: p-value after genomic control 
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Table 3.9 Gene-based analysis in LPA region conditioning on the top two variants 
identified in single-variant analysis  
 
Gene P β SE nsnpsTotal nsnpsUsed   
LPA 1.2E-21 -0.40 0.04 45 24   
 2.1E-14 -0.34 0.04 44 23 after adjusting for rs41272114 
 5.7E-09 -0.33 0.06 43 22 after adjusting for rs41272114 and rs41272110 
 
Gene-based analysis is level 3 Madsen-Browning test (including stop-altering, splice-site, and 
non-synonymous variants with MAF <0.03); 
rs41272114: the strongest associated variant in LPA region identified in single-variant analysis, 
p=6.5E-12;  
rs41272110: the second strongest associated variant in LPA region identified in single-variant 
analysis, p=2.4E-06; 
nsnpsTotal: total number of Exome-chip variants in the LPA gene; 
nsnpsUsed: number of Exome-chip variants in the LPA gene that were included in the level 3 
Madsen-Browning test. 
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Figure 3.1 The LOD score of genome-wide admixture scan for Lp(a). The LOD score is 
defined as the log base 10 ratio of the maximum likelihood of the data under a local-ancestry-
associated disease model divided by the likelihood of the data under null model. Both alternative 
and null model include covariate adjustment for global ancestry. Positive LOD scores show the 
association of increased African ancestry with higher levels of Lp(a), while negative LOD scores 
show the association of increased African ancestry with lower level of Lp(a). 
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(A)       (B) 
 
(C)       (D) 
Figure 3.2 Quantile-Quantile (Q-Q) plots of the P-values tested for association with Lp(a) 
across (A) all SNPs, (B) all remaining SNPs after excluding SNPs on chromosome 6, (C) all 
SNPs after controlling for inflation factor λ, and (D) all remaining SNPs after excluding SNPs on 
chromosome 6 and after controlling for inflation factor λ.  
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Figure 3.3 Manhattan plot of the -log10(P) values by chromosome for Lp(a)  
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(A) 
 
(B) 
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(C) 
 
Figure 3.4 Regional plot of the -log10(P) values for the SNPs in the chromosome 6q region 
for Lp(a) (A) before adjusting for any SNPs, (B) after adjusting for the top SNP 
rs115848955 at this locus, and (C) after adjusting for the local ancestry estimate rs6923917. 
The X axis shows the human genome build 19 coordinates (Mb) and the genes in the region. The 
Y axis shows the -log10 association P values of SNPs on the left, and recombination rates in cM 
per Mb on the right. Different colors of shading indicate the strength of linkage disequilibrium 
(LD) (r
2
) between the top SNP and the other SNPs tested in the region. 
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Figure 3.5  Haploview screen showing an LD plot of 15 reprioritized SNPs (RMIP >0.75) in 
the 1 Mb hit region on chromosome 6. Each square displays the LD D’ value between a pair of 
SNPs. The strength of LD between two SNPs is displayed by the intensity of the color of a 
square.  Thick black triangles depict haplotype blocks by default definition used in Haploview. 
SNP rs6415084, rs3798221, rs9457986, rs1367211, and rs1406888 were on the LPA gene.  
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CHAPTER IV: A VARIANT NEAR FGF5 HAS STRONGER EFFECTS ON BLOOD 
PRESSURE IN CHINESE WITH A HIGHER BODY MASS INDEX 
3
 
 
Introduction 
Hypertension is an important risk factor for cardiovascular disease (CVD), the leading 
cause of mortality all over the globe (40). Hypertension is a worldwide problem(146) and its 
prevalence is increasing in China(147). According to the data from 2007-2008 China National 
Diabetes and Metabolic Disorders Study, 26.6% of Chinese adults have hypertension(147), 
causing considerable health and economic burden(148, 149).  
The etiology of high blood pressure involves the interplay among many factors. Risk 
factors include body mass index (BMI), tobacco use, salt and alcohol intake, and physical 
activity(46). An estimated 30-60% of blood pressure variation is explained by genetic factors(49). 
Many genetic variants have been identified by genome-wide association studies (GWAS) 
conducted in multiple populations. Blood pressure is a complex phenotype, and the effects of 
some variants may be stronger in individuals exposed to specific environmental factors. 
However, relatively few studies have investigated the possible interaction between genetic 
variants and environmental factors in affecting blood pressure.  
Several loci first identified in subjects of European descent, including ATP2B1 on 
chromosome 12q21.33, FGF5 on 4q21.21, CYP17A1 on 10q24.32 and CSK on 15q24.1 have 
been validated in East Asians(59, 150). In this study, we genotyped index variants from these
                                                 
3
 A version of this work was previously published as Li J et al. Am J Hypertens. 2015 Jan 23. pii: hpu263 [Epub 
ahead of print] 
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four candidate loci and examined whether the associations with systolic (SBP) and diastolic 
(DBP) blood pressure could be replicated in 7,319 adults (18 years and older) from 9 provinces 
in the China Health and Nutrition Survey (CHNS). We further tested whether the associations 
were influenced by environmental factors including age, sex and BMI. Finally, we attempted to 
replicate specific findings in 1,996 men from the Fangchenggang Area Male Health and 
Examination Survey (FAMHES). 
 
Materials and methods 
Study design 
The China Health and Nutrition Survey (CHNS) is a nationwide longitudinal survey 
designed to examine a series of economic, sociological, demographic, and health questions in the 
Chinese population. The design of CHNS has been described in detail elsewhere(151).  This 
study was conducted in nine provinces in China that vary significantly in terms of socioeconomic, 
health-related, and nutritional status. The sample from each province was drawn using a 
multistage, random cluster procedure, designed to select a stratified probability sample in each 
province, with selection of larger cities and smaller suburban and rural villages, from which 
households were randomly selected. Approximately 19,000 individuals from ~4,400 households 
participated in the overall survey. The first round of data was collected in 1989, followed by 
eight additional waves of data collected in 1991, 1993, 1997, 2000, 2004, 2006, 2009, and 2011. 
The study was approved by the ethics committee at the National Institute of Nutrition and Food 
Safety at the China Center for Disease Control and Prevention and the Institutional Review 
Board at the University of North Carolina at Chapel Hill. Written consent was obtained from 
subjects surveyed in 2009.  
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Data collection and phenotypes 
For this study, we used dietary, clinical, and anthropometric data collected from 
participants who were age 18 years or older and not pregnant at the time of the 2009 survey. 
Blood pressure was measured three consecutive times on the same day, with 10 minutes of 
seated rest before the first measurement and 3-5 minutes intervals between each measurement. 
SBP and DBP were determined by the first and fifth phase Korotkoff sounds(152), respectively. 
The average of the three measurements was used for analyses.  For participants who take 
antihypertensive medications, 10 and 5 mm Hg was added to the average SBP and DBP, 
respectively(153) (154). The smoking responses were dichotomized to define current smoking 
status.  Total salt intake (grams) was estimated based on a combination of three consecutive 24-
hour food recalls at the individual level and a food inventory at the household level(155).  
 
Genotyping 
Fasting venous blood was collected and stored at -80 °C, and DNA was extracted from 
buffy coat using the FlexiGene DNA kit (Qiagen, Valencia, CA, USA), according to the 
manufacturer’s instructions. Four candidate variants for blood pressure(150), including 
rs11105378 at ATP2B1, rs1458038 at FGF5, rs1004467 at CYP17A1, and rs1378942 at CSK-
CYP1A1, were genotyped using TaqMan chemistry (Applied Biosystems). TaqMan genotyping 
assays with probes labeled with the fluorophores FAM and VIC were purchased from Applied 
Biosystems. The Universal PCR Master Mix from Applied Biosystems was used in a 5 µl total 
reaction volume with 10 ng DNA per reaction. Allelic discrimination was measured 
automatically on ABI Prism 7900HT (Applied Biosystems) with Sequence Detection Systems. 
Among 8,221 individuals genotyped, the success rate for each variant was >98%. Genotype 
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distributions were consistent with Hardy-Weinberg equilibrium expectations (P > 0.05). The 
concordance rate between 301 duplicate pairs across all variants was >99.9%.  
 
Statistical analyses 
A total of 7,319 non-pregnant adults, age 18 years or older at the time of blood pressure 
measurement, with complete phenotype, covariate and genotype data were included in tests of 
association between variants and SBP or DBP. The distributions of SBP and DBP, after 
accounting for age, sex and BMI, showed no significant deviation from normality; 
untransformed traits were analyzed. Linear mixed-effects models(156), with a random effect for 
household to account for the unaccounted for correlation between blood pressure measurements 
from members in the same family, were used to test the variant additive genetic main effects. 
The base models included adjustment for covariates significantly (P < 0.05) associated with SBP 
or DBP, age, sex, province and BMI. Additional models also included covariate adjustment for 
current smoking status and total salt intake.  Each variant that showed evidence for a main effect 
association (P < 0.05) with either SBP or DBP was further analyzed for variant-by-environment 
interactions with age, sex, and BMI by including an interaction term to the above base linear 
mixed-effects model. Stratified analyses were performed for variants demonstrating evidence of 
a significant interaction (Pinteraction < 0.05) by categorizing participants according to quartiles of 
the environmental factor and testing main effects of the variants within each quartile.  
 
Follow-up sample 
 We followed up our genotype-by-BMI interaction finding at rs1458038 near FGF5 in 
1,996 men from the FAMHES study using linear regression models with covariate adjustment 
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for age and the main effects for genotype and BMI.  As with CHNS, we also performed stratified 
analyses for the main effects of rs1458038 on SBP and DBP in strata defined by BMI quartiles 
of the FAMHES participants. As described in Yang et al(157), the FAMHES project was 
conducted in Fangchenggang city, Guangxi, southern China in 2009. A total of 4,303 Chinese 
men ranged from age 17 to 88 years old were recruited(158). The subjects used in our current 
study were limited to men aged 20 to 69 years old (average age 37.5 ± 11.1 years) of self-
reported southern Chinese Han ethnicity. 50.8% of men were reported smokers and the average 
BMI was 23.1 ± 3.4 kg/m
2
). Written informed consent to participate in the study was provided 
by all participating men. The Illumina HumanOmni1-Quad BeadChip was used to perform 
genome-wide assay of all samples. Trained nurses obtained a single measure of blood pressure 
on each FAMHES participant by applying a mercury sphygmoma nometer to the right arm of the 
participants when they were seated in a comfortable sitting position after an at least 5-minute rest 
period. Participants were asked to avoid vigorous exercise, drinking, and smoking for at least 30 
minutes prior to the measurement. Medication history related to hypertension was not available. 
   
Results 
 Overall, 7,319 CHNS subjects (3,987 females and 3,332 males) with complete phenotype 
(average SBP and DBP), essential covariates (age, sex, BMI, province), and genotype data were 
included in the analyses (Table 4.1). Higher age, male sex, larger BMI, and current smoking 
were each associated with higher SBP and DBP (data not shown, P < .05). Higher salt intake was 
associated with higher DBP. Province was also associated with blood pressure levels. Blood 
pressure levels were higher in residents from Northern provinces than in residents from Southern 
provinces (Table 4.2), which is consistent with the north-south gradient in the prevalence of 
 91 
 
hypertension in China observed in another cross-sectional survey(159). When all of these 
covariates were included in a single model, current smoking status and total salt intake no longer 
showed evidence for association with SBP or DBP. Current smoking status was missing on 4 
subjects and total salt intake was missing on 256 subjects. Thus our base model, Model 1, 
included covariates for age, sex, BMI and province while our secondary model, Model 2, had 
additional covariates for current smoking status and total salt intake. 
 Four candidate variants that were previously reported to be associated with SBP and/or 
DBP in prior studies (49) (59) (150) (160) (161) were tested for association with these traits in 
the CHNS study. Two variants (rs11105378 near ATP2B1 and rs1458038 near FGF5) were 
significantly associated (P < 0.00625 = 0.05/8) with both SBP and DBP (Table 4.3). Variant 
rs1378942 near CSK was nominally associated with SBP (P = 7.0x10
-3
).  The direction and 
effect size for all eight association tests were consistent with the previous reports.  Additional 
covariate adjustment for current smoking status and total salt intake resulted in very similar 
findings compared to the base model without these covariates (data not shown). 
 The three variants associated (P < 0.05) with SBP and two variants associated with DBP 
were tested for interaction with each of three environmental factors (age, sex, and BMI) that 
significantly affected blood pressure when controlling for all other covariates. Among the 15 
tests performed, four showed nominally significant results (Pinteraction < 0.05). The observed 
interaction between rs1458038 and BMI on SBP was significant (Pinteraction = 0.0018; β=0.25) 
after Bonferroni correction for multiple tests (Pinteraction < 0.0033, 0.05/15 tests). The interaction 
between rs1458038 and BMI was also nominally associated (Pinteraction = 0.049, β = 0.10) with 
DBP. The two remaining nominally significant interactions were between rs1378942 and sex on 
SBP (Pinteraction = 0.045, β = 1.54) and between rs11105378 and age on DBP (P = 0.026, β = 0.03).  
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Further analyses stratified by BMI levels were conducted in CHNS to interrogate the 
interactions between rs1458038 and BMI on SBP and DBP. We stratified the samples according 
to BMI quartiles and performed main-effects regression analyses of rs1458038 on SBP and DBP, 
adjusting for the secondary model covariates. The T allele of rs1458038 was significantly 
associated with higher SBP in the highest quartile of BMI (Q4: P = 1.9x10
-6
), but the association 
was not significant in lower quartiles (Q1: P = 0.69; Q2: P = 0.11; Q3: P = 5.7x10
-2
) (Table 4.4). 
The magnitude of the effect size estimates increased with BMI (Q1: β = 0.21; Q2: β = 0.88; Q3: 
β = 1.05; Q4: β = 2.93). A similar pattern of interaction of this variant with BMI was observed in 
its effects on DBP.  Here too, rs1458038 genotype had stronger main effects on DBP in 
individuals with the largest BMI (Q1: β = 0.33, P = 0.34; Q2: β = 0.12, P = 0.72; Q3: β = 0.80, P 
= 2.1x10
-2; Q4: β = 1.23, P = 1.0x10-3; Table 4.4). 
In FAMHES, there was a trend (P ≤ 0.10) with consistent direction of effects to CHNS, 
for main effects of rs1458038 on both DBP (P = 0.058) and SBP (P = 0.10) (Table 4.5). The 
interaction effects between rs1458038 and BMI affecting SBP and DBP were in the same 
direction as CHNS but did not reach statistical significance in FAMHES (Pinteraction = 0.36 for 
DBP; Pinteraction = 0.62 for SBP).  Consistent with CHNS, the estimates of the main effects of 
rs1458038 on SBP (Q1: β = 1.10; Q2: β = 0.37; Q3: β = 1.02; Q4: β = 1.63) and DBP (Q1: β = 
0.44; Q2: β = 0.68; Q3: β = 0.49; Q4: β = 1.59) were strongest in men grouped in the highest 
quartile of BMI (Table 4.6). The association between rs1458038 and DBP was nominally 
significant (P = 0.034) only in the highest BMI quartile. Because FAMHES only contained 
males, we could not assess the interaction between rs1378942 and sex on SBP. Finally, due the 
absence of evidence for main effects at rs11105378 (P = 0.96), we did not assess the evidence 
for an interaction between this SNP and age on DBP in FAMHES. 
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Discussion 
In this study, we tested the association of four candidate variants with SBP and DBP in 
7,319 Chinese individuals, from nine provinces, participating in the CHNS and followed up our 
top findings in 1996 Chinese men from the province of Guangxi participating in FAMHES. 
Rs1458038, upstream of FGF5 on chromosome 4 and rs11105378, upstream of ATP2B1 on 
chromosome 12 were significantly associated with both SBP and DBP (P < 0.00625) in CHNS 
while rs1378942, an intronic variant in CSK, was nominally associated with SBP (P = 7.0x10
-3
). 
Most interestingly, in CHNS, we detected a significant interaction between rs1458038 and BMI 
affecting SBP and a nominally significant interaction between this same variant and BMI 
affecting DBP. Specifically, we showed that the effect of the rs1458038 risk genotype is 
considerably stronger in subjects in the heaviest quartile of the BMI distribution.  
Rs1458038, 5’ of FGF5, was identified in Europeans(160), and also confirmed in 
Japanese(150). Located at chr4:81164723, rs1458038 is ~23 kb upstream of the transcription 
staring site of FGF5 (chr4:81187742). The association of nearby variant rs16998073 
(chr4:81184341, LD r
2 
= 0.917 in CEU) was identified in East Asians(59) (162) (163) and 
Europeans(161). Rs11105378, an intronic variant in ATP2B1, was identified by the CHARGE 
and Global BPgen Consortia (49), and confirmed in Japanese (150). Several other variants that 
are in high LD with rs11105378 (r
2 
> 0.8 in CEU) were also identified in different ethnicities (49, 
59, 160, 164). Differences in ATP2B1 mRNA expression levels in umbilical artery smooth 
muscle cells were observed among different rs11105378 genotypes (150). To our knowledge, no 
study has provided any evidence that either rs1458038 or rs16998073 are in any promoter or 
enhancer regions. We replicated the associations of these two variants with both SBP and DBP, 
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reaffirming the importance of these variants on blood pressure in the Chinese population. 
Rs1378942, an intronic variant 2,306 bp from a splice site in CSK, was significantly associated 
with SBP and DBP in Europeans(160); however, only nominal association was observed in East 
Asians(59) and Japanese(150). In our study, we only replicate (P < 0.05) its association with 
SBP, although the effect size estimates for both SBP and DBP were similar in both direction and 
size to the previous study in Japanese. We failed to replicate blood pressure associations with 
rs1004467, an intronic variant 35 bp from a splice-site in CYP17A1. Here too, our directions of 
effect were consistent with the previous Japanese study. However, the size of the effects for DBP 
and SBP were about half of those reported previously for this variant.  
An interesting finding of this study is the evidence for interaction between rs1458038 5’ 
of FGF5 at 4q21 and BMI in affecting both SBP and DBP in CHNS. BMI is a strong risk factor 
that affects blood pressure; the prevalence of hypertension and mean levels of SBP and DBP 
increase as BMI increases(165, 166). While variants 5’ of FGF5 at 4q21 are associated with 
blood pressure in the Chinese population(162, 163), the interaction between these two risk 
factors on affecting blood pressure has not been previously reported. In our study, the increasing 
differences in blood pressure between rs1458038 TT, CT and CC carriers with increasing BMI 
support the hypothesis that larger BMI enhances the effects of the rs1458038 risk allele on 
increasing blood pressure. The strongest evidence for association between rs1458038 and the 
blood pressure measures in CHNS were observed in the highest quartile of BMI. In FAMHES, 
the strongest effects of rs14358038 for both blood pressure traits were also observed in the 
highest quartile of BMI. The observed main effects of rs14358038 in the highest BMI quartile of 
FAMHES men were ~50% larger than in any other quartile for SBP and more than twice as large 
as the estimated effects in any other quartile for DBP. While the tests of rs14358038-BMI 
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interaction on the blood pressure measures were not significant in FAMHES, they were 
directionally consistent with CHNS.  
When assessing the overall impact of the FAMHES results, some differences between 
CHNS and FAMHES are worth noting. FAMHES includes only males from the province of 
Guangxi, while CHNS includes both males and females from nine provinces, including Guangxi.  
The sample size of FAMHES (n=1,996) is considerably smaller than that of CHNS (n=7,319).  
FAMHES men were also younger, on average, than CHNS individuals (average age = 37.5 years 
of age in FAMHES and 50.8 years of age in CHNS). Both the average SBP and DBP measures 
were lower in FAMHES men compared to CHNS men; however, these results are consistent 
with the younger ages in FAMHES and the lower blood pressure values observed in CHNS men 
from Guangxi. SBP and DBP were measured only once in FAMHES compared to three 
measurements (we applied the average) in CHNS. Finally, no hypertensive medication history 
was available in FAMHES. In CHNS, 399 subjects were known to be on hypertensive 
medication and an offset was applied to the SBP and DPB measures in CHNS to account for 
medication use. 
An interaction between variants at 4q21 and BMI in affecting blood pressure is 
biologically plausible. Four genes including ANTXR2, PRDM8, FGF5, and C4orf22 are located 
near rs1458038. ANTXR2 encodes anthrax toxin receptor 2, a protein involved in 
angiogenesis(167). A recent functional study(168), using in vivo small interfering RNA (siRNA) 
silencing in mice, suggested ANTXR2 is the most likely causative gene in the 4q21 region that 
regulates individual differences in blood pressure in humans. The study proposed that the lower 
Antxr2 expression can lead to a decrease in the proliferation of endothelial cells, prevent the 
formation of capillary network, and result in microvascular rarefaction and increase of BP.  
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Many studies observed a developing microvascular rarefaction within skeletal muscle during the 
metabolic syndrome including obesity, insulin resistance/type II diabetes mellitus, dyslipidemia, 
and hypertension. (169, 170). Microvascular dysfunction is a potential mechanism in the 
pathogenesis of obesity-associated insulin resistance and hypertension(171, 172). In addition to 
ANTXR2, FGF5 is also possibly involved in the metabolic syndrome. FGF5 encodes fibroblast 
growth factor 5, a member of the fibroblast growth factor (FGF) family. Several members of the 
FGF family have been shown to affect obesity by regulating fatty acid oxidation and lipid 
metabolism. Treatment with exogenous recombinant human FGF21 protein via infusion or 
injection can lead to weight loss and improvement of lipid profiles in diet-induced obese (DIO) 
mice(173) and diabetic rhesus monkeys(174). Transgenic mice expressing human FGF19 
display increased metabolic rate and decreased adiposity(175). Although FGF5 has not yet been 
shown to have a direct effect on BMI, this member of the FGF family may also play a role in 
regulating metabolism and affecting obesity. The role of PRDM8 and C4orf22 in the 
pathogenesis of obesity and hypertension is not known.  
In conclusion, the association of rs11105378 near ATP2B1 and rs1458038 near FGF5 
with both SBP and DBP were replicated in CHNS. In addition, the magnitude of the associations 
between rs1458038, 5’ of FGF5, and blood pressure were modified by BMI in CHNS 
individuals. While we were unable to formally replicate the interaction in a second Chinese 
cohort, evidence from both studies implicate that the risk genotype at rs1458038 is particularly 
important in Chinese individuals with higher BMI. To our knowledge, this is the first reported 
interaction between a variant in or near FGF5 and BMI on blood pressure. Further studies in 
Chinese and other populations are needed to confirm this finding.  
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Table 4.1 Characteristics of the China Health and Nutrition Survey participants analyzed 
 
Characteristics Female (n=3,987) Male (n=3,332) Total(n=7,319) 
 
mean ± SD median (range)  mean ± SD median (range) mean ± SD median (range) 
SBP (mm Hg) 124.3 ± 20.8 120.0 (76.7, 266.7) 126.8 ± 18.2 122.0 (80.0, 229.3) 125.4 ± 19.7 121.0 (76.7, 266.7) 
DBP (mm Hg)   79.4 ± 11.6   80.0 (44.0, 152.0)   82.5 ± 11.3   80.7 (50.0, 136.0)   80.8 ± 11.6   80.0 (44.0, 152.0) 
Age (years)   50.9 ± 15.0 51.1 (18.0, 98.9)   50.7 ± 15.1 51.0 (18.0, 92.3)   50.8 ± 15.0   51.0 (18.0, 98.9) 
BMI (kg/m
2
) 23.4 ± 3.5 23.0 (13.4, 38.8) 23.4 ± 3.4 23.2 (13.4, 37.2) 23.4 ± 3.5  23.1 (13.4, 38.8) 
Current smoker (%) 3.70% - 55.00% - 27.04% - 
Total salt intake (grams)   4.5 ± 2.6     3.9 (0.1, 22.2)   4.9 ± 2.7    4.3 (0.2, 21.3)   4.7 ± 2.6     4.1 (0.1, 22.2) 
 
Values are means ± SD, medians (range), or %. The average of the three measurements of SBP or DBP was used for analysis. Total 
salt intake was based on a combination of three consecutive 24-hour food recalls at the individual level and a food inventory at the 
household level. The sample size is 7,315 with data on current smoking status and 7,063 with data on total salt intake.  
SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index.  
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Table 4.2 Mean levels of SBP and DBP in residents from each province 
Province Number Female Male Total Sample Size Province 
Name 
Range of Latitude 
SBP (mm Hg)       
province=23 124.7 ± 21.2 127.3 ± 16.0 125.9 ± 19.0 768 Heilongjiang (43.2°, 53.3°) 
province=21 130.3 ± 21.7 131.0 ± 19.8 130.6 ± 20.9 719 Liaoning (38.4°, 43.3°) 
province=37 126.8 ± 16.2 130.8 ± 16.8 128.6 ± 16.6 835 Shandong (34.2°, 38.2°) 
province=41 122.8 ± 19.3 125.6 ± 17.3 124.0 ± 18.5 776 Henan (31.2°, 36.2°) 
province=32 125.2 ± 20.8 128.8 ± 18.5 126.9 ± 19.8 1004 Jiangsu (30.4°, 35.2°) 
province=42 122.9 ± 22.5 126.7 ± 18.6 124.6 ± 20.9 729 Hubei (29.0°, 33.2°) 
province=43 123.8 ± 23.9 124.5 ± 18.5 124.1 ± 21.6 969 Hunan (24.4°, 30.1°) 
province=52 119.8 ± 19.7 125.4 ± 19.7 122.3 ± 19.9 564 Guizhou (24.4°, 29.1°) 
province=45 121.7 ± 19.4 121.6 ± 16.7 121.7 ± 18.2 955 Guangxi (20.5°, 26.2°) 
DBP (mm Hg)       
province=23 82.9 ± 13.2 85.5 ± 11.4 84.1 ± 12.4 768 Heilongjiang (43.2°, 53.3°) 
province=21 83.5 ± 11.6 85.7 ± 11.3 84.5 ± 11.5 719 Liaoning (38.4°, 43.3°) 
province=37 81.3 ± 10.0 85.3 ± 10.5 83.1 ± 10.4 835 Shandong (34.2°, 38.2°) 
province=41 80.1 ± 11.1 83.8 ± 10.5 81.8 ± 11.0 776 Henan (31.2°, 36.2°) 
province=32 79.7 ± 11.0 83.5 ± 10.9 81.5 ± 11.1 1004 Jiangsu (30.4°, 35.2°) 
province=42 76.9 ± 11.8 80.0 ± 10.6 78.3 ± 11.4 729 Hubei (29.0°, 33.2°) 
province=43 76.8 ± 11.8 79.8 ± 11.8 78.2 ± 11.9 969 Hunan (24.4°, 30.1°) 
province=52 77.4 ± 11.4 81.1 ± 13.0 79.1 ± 12.3 564 Guizhou (24.4°, 29.1°) 
province=45 77.0 ± 10.6      78.7 ± 9.9 77.8 ± 10.3 955 Guangxi (20.5°, 26.2°) 
 
Values for SBP and DBP are mean ± SE. 
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Table 4.3 Main effect association of variants with SBP and DBP in CHNS 
      Model 1  Model 2 
Variant Chr Nearby Gene EA EAF Trait Sample β SE P Sample β SE P 
rs1458038 4 FGF5 T 0.42 SBP 7,272 1.29 0.28 2.8E-06 7,013 1.28 0.28 5.9E-06 
     DBP  0.70 0.17 5.2E-05  0.68 0.18 1.1E-04 
rs1004467 10 CYP17A1 A 0.65 SBP 7,308 0.37 0.29 0.20 7,048 0.44 0.29 0.13 
     DBP  0.11 0.18 0.54  0.13 0.18 0.49 
rs11105378 12 ATP2B1 C 0.66 SBP 7,187 1.22 0.29 3.3E-05 6,929 1.29 0.30 1.8E-05 
     DBP  0.73 0.18 6.9E-05  0.80 0.19 1.8E-05 
rs1378942 15 CSK C 0.84 SBP 7,276 1.02 0.38 7.0E-03 7,018 0.97 0.39 0.012 
     DBP  0.35 0.24 0.14  0.36 0.24 0.14 
 
 coefficients represent the estimated change in the level of blood pressure associated with each 
additional copy of the effect allele, designed as the blood pressure raising allele. Covariates for 
model 1 were age, gender, province, and BMI. Covariates for model 2 were age, gender, 
province, BMI, current smoking status, and total salt intake. 
EA: effect allele; EAF: effect allele frequency; SE: standard error 
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Table 4.4 Mean levels of SBP and DBP by rs1458038 genotype and BMI quartile in CHNS. 
 
  All participants CC CT TT N β (SE) P 
SBP 
       
Q1 118.9 ± 18.6 118.7 ± 18.3 118.7 ± 18.2 120.1 ± 20.0 1818 0.21 (0.54) 0.69 
Q2 122.8 ± 18.2 121.7 ± 17.4 123.0 ± 18.1 124.7 ± 20.2 1818 0.88 (0.55) 0.11 
Q3 127.1 ± 18.7 126.2 ± 18.6 127.2 ± 18.1 128.6 ± 20.4 1818 1.05 (0.55) 0.057 
Q4 132.8 ± 20.4 130.8 ± 19.2 133.4 ± 20.7 135.1 ± 21.6 1818 2.93 (0.61) 1.9E-06 
        
DBP 
       
Q1 76.4 ± 10.9 76.0 ± 10.6 76.4 ± 10.8 77.1 ± 11.6 1818 0.33 (0.34) 0.34 
Q2 78.9 ± 10.8 78.7 ± 10.8 79.1 ± 10.6 78.9 ± 11.4 1818 0.12 (0.34) 0.72 
Q3 82.2 ± 10.8 81.4 ± 11.0 82.5 ± 10.4 83.0 ± 11.3 1818 0.80 (0.34) 0.021 
Q4 85.7 ± 11.7 85.1 ± 11.7 85.6 ± 11.9 87.4 ± 11.2 1818 1.23 (0.38) 1.0E-03 
 
Q1-Q4: the lowest BMI quartile to the highest BMI quartile 
Q1: BMI <20.93; Q2: 20.93≤BMI<23.11; Q3: 23.11≤BMI<25.65; Q4: BMI≥25.65. Values for 
SBP and DBP are mean ± SE. 
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Table 4.5 Main effect association of rs1458038 with SBP and DBP in FAMHES 
Variant Chr. Nearest 
Gene 
EA EAF Trait Sample β SE P 
rs1458038 4 FGF5 T 0.42 SBP 1996 0.80 0.49 0.10 
     DBP 1996 0.62 0.33 0.058 
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Table 4.6 Mean levels of SBP and DBP by rs1458038 genotype and BMI quartile in 
FAMHES. 
 
  All participants CC CT TT β (SE) P 
SBP 
      
Q1 113.3 ± 13.2 112.7 ± 13.6 112.8 ± 13.1 115.1 ± 12.9 1.10 (0.82) 0.18 
Q2 116.6 ± 14.4 116.4 ± 15.7 116.6 ± 14.2 117.1 ± 12.2 0.37 (0.92) 0.69 
Q3 118.6 ± 14.8 117.7 ± 14.0 118.8 ± 14.8 119.7 ± 16.6 1.02 (0.94) 0.28 
Q4 124.3 ± 17.1 122.9 ± 15.8 124.8 ± 16.8 126.0 ± 20.6 1.63 (1.12) 0.15 
       
DBP 
      
Q1 73.5 ± 8.8 73.3 ± 9.3 73.2 ± 8.7 74.3 ± 8.6 0.44 (0.55) 0.43 
Q2 75.0 ± 9.3 74.2 ± 9.9 75.6 ± 9.4 75.3 ± 8.2 0.68 (0.60) 0.26 
Q3 77.5 ± 9.2 77.0 ± 9.1 77.8 ± 8.8 77.9 ± 10.4 0.49 (0.58) 0.40 
Q4 81.6 ± 11.5 80.1 ± 10.3 82.2 ± 11.3 83.0 ± 14.0 1.59 (0.75) 0.034 
 
Q1-Q4: the lowest BMI quartile to the highest BMI quartile 
Q1: BMI <20.80; Q2: 20.80≤BMI<23.04; Q3: 23.04≤BMI<25.50; Q4: BMI≥25.50. Values for 
SBP and DBP are mean ± SE. 
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CHAPTER V: USE OF SELECTIVE PHENOTYPING TO INCREASE POWER OF 
TWO-STAGE GENETIC ASSOCIATION STUDIES FOR BOTH GENOTYPED AND 
IMPUTED DATA 
4
 
 
Introduction 
        Genome-wide association studies (GWASs) are a powerful method for identifying common 
genetic variants contributing to human disease(176). GWASs require genotyping a large number 
of genetic markers on a large number of subjects. Cost-efficient sample selection for GWASs is 
often necessary due to budget limitations. In the past, the expense of genotyping has been the 
main cost constraint. Today, chip-based high-throughput technologies have dramatically 
decreased genotyping costs and, as a consequence, genotype data is routinely available on large 
numbers of potential study subjects. Much of the burden of expense has now shifted from the 
cost of genotyping to the cost of phenotyping new traits, especially when phenotyping involves 
mRNA abundance data obtained from microarray experiment, novel blood-based biomarkers or 
complex physiological and behavioral traits. Selective phenotyping can be a powerful approach 
for increasing the power of genetic association studies that are under trait-measurement-related 
sample size constraints (77). The approach utilizes available genetic information on the complete 
sample to select a subset of individuals for phenotyping that will improve statistical power for 
the markers of greatest interest. 
            Two-stage GWASs have been routinely applied during the past decade to increase 
statistical power and reduce genotyping costs. Herein, we describe a novel two-stage selective-
                                                 
4
 A version of this work will be submitted for publication. 
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phenotyping design that will increase the power for GWAS studies, with existing genetic data 
and to-be-measured newly quantitative traits. To date, selective-phenotyping designs have been 
proposed for single-stage genetic association studies, where the markers of greatest interest have 
already been determined. A GWAS is typically a discovery-based study, where the identification 
of the “interesting” markers is the overarching goal of the study. Thus, it stands to reason that 
before we can apply selective phenotyping in a meaningful way, we first have to identify which 
markers we should focus the phenotype selection on. This dynamic is a natural fit for a two-stage 
selective-phenotyping design, where in the first stage the investigators phenotype a random 
subset of subjects to identify the most promising markers and then in the second stage the 
investigators use their remaining resources to carefully select a fraction of the remaining subjects 
to phenotype based on their observed genotypes for these most promising markers. We show that 
combining the data from the two stages results in greater statistical power for discovery 
compared to the default method of simply selecting the same number of random subjects to 
phenotype for a single-stage association study. 
       Methods to maximize power using selective phenotyping have been described previously, 
albeit for considerably smaller studies than a GWAS (78-81). The common rationale behind 
these methods is to identify the subset of subjects who are as genetically dissimilar as possible 
with respect to distributions of marker genotype data across all markers of interest. If only a 
single marker is of interest, then selecting an equal number of homozygotes for the minor and 
major allele for that marker to phenotype would be the optimal strategy for most plausible 
inheritance models (i.e. if we ignore the possibility of overdominance). The maximization of 
genotypic diversity simultaneously across multiple markers is a complex optimization problem, 
as some subjects who have the less common homozygous genotype for some markers of interest 
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could also have the more common homozygous genotypes for other markers of interest. The 
computation complexity of the problem grows quickly as the number of target markers (e.g. 
those markers determined to be of interest for the phenotype-selection optimization) increases. 
            Simulated annealing (SA) is a computationally efficient algorithm for complex 
optimization problems, such as finding the global minimum or maximum of functions containing 
many variables (177, 178)
,
(179). In this study, we describe a selective-phenotyping method that 
uses SA to identify the optimal subset of subjects to be phenotyped in Stage 2 of a two-stage 
GWAS, based on their available directly genotyped or imputed dosage data across multiple 
markers of interest, as determined by the results from a subset of randomly phenotyped subjects 
used in Stage 1. We then combine the results from the two stages using a joint-analysis approach 
to assess the overall significance of all markers, including those not included in the Stage 2 
selection process, as all samples will have available phenotypic and genetic data on all available 
genotyped and imputed markers. Critical parameterization of the two-stage approach includes the 
proportion of available subjects to phenotype in Stages 1 versus Stage 2 and number of markers 
to include in the phenotype-selection process in Stage 2. To underscore this point, power is 
ideally optimized when the truly, and only truly, associated markers are selected for the Stage 2 
optimization process that is allowed to consider the largest possible sample of subjects available 
for phenotyping. The probability of the true markers being included in the Stage 2 selective-
phenotyping optimization can be increased by either increasing the proportion of subjects to be 
randomly phenotyped in Stage 1 or by increasing the number of markers included in the Stage 2 
selection algorithm, however, the trade-off is that either fewer samples are then available for the 
Stage 2 selection strategy or the proportion of true markers included in the optimization 
algorithm is likely diluted thereby reducing the benefits of the phenotype-selection algorithm. 
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Materials and methods 
Simulated-annealing algorithm for selective phenotyping 
In this study, we use a SA-based algorithm to maximize the leverage of specific targeted 
markers by selecting subjects to phenotype from the larger cohort pool that maximizes the 
average genotype dispersion across that set of targeted genotyped markers included in the 
selection process. For a targeted marker, increasing the dispersion, or variance, of the marker 
genotypes will result in greater expected precision of the regression coefficient that describes the 
relationship between the outcome measure and the marker, leading to greater statistical power to 
identify a significant association between the outcome and the marker when such a relationship 
exists.  For a given marker j, the dispersion = ∑          
  
    which we label as   , is the sum 
of the squared difference between each of the n subjects genotypes and the overall genotypic 
mean, where genotype is scored 0, 1 or 2 for each subject corresponding to the carried number of 
copies of the minor allele. We further define the average of    across m target markers as 
 = 
∑   
 
   
 
 = 
∑ ∑          
  
   
 
   
 
.  
Parameters in our simulated annealing algorithm include the function to be optimized 
 = 
∑   
 
   
 
 = 
∑ ∑          
  
   
 
   
 
, the initial temperature (  ), the rate of cooling ( ) and the 
convergence criteria ( ). We assume that we have access to genotype data on        subjects 
across  (=1,000,000) markers prior to phenotype sample selection, but we can only afford to 
measure the phenotypes of         subjects (                ) in total. We refer to 
          as the proportion of these         subjects to be phenotyped in Stage 1, so that 
                         subjects are phenotyped in Stage 1 and              
 108 
 
                subjects are phenotyped in Stage 2. We refer to           as the 
proportion of markers to be used in the SA algorithm for selecting the    subjects, from the 
       –     possible subjects, to be phenotyped in Stage 2; thus, (                ) 
candidate markers are used in the SA algorithm to select subjects for phenotyping in Stage 2. We 
denote    as subject i,   as the set of    subjects in Stage 1 so that   ={     , …   },   
  as a 
set of    subjects selected in Stage 2 from the complete (         ) sample at iteration k so 
that   
 ={           , …      }. We denote     
 as a set of         subjects after 
combining the    subjects in Stage 1 and    subjects selected in Stage 2 at iteration k together, 
so that     
       
 . We denote   
  as the set of (            ) subjects left at 
iteration k so that   
 ={                 , …      }. Let    
    =   
       , where    is 
a subject a randomly selected from   
  and removed from   
  , and    is a subject b randomly 
selected from   
  and added to   
   . Thus,     
   =     
   . Let  
 
 =  
∑ ∑          
   
   
  
   
  
 for set 
of subjects i    
 , respectively. Our goal is to iteratively maximize   using simulated annealing. 
The iterative approach is as follows:  
1) Select a random    (Stage 1 samples) and to be removed from possible Stage 2 
samples.  
2) Set   , the starting temperature,  , the constant cooling rate, and  , the user-defined 
threshold for convergence. 
3)  Randomly select initial random Stage 2 sample   
 , and calculate  
 
based on   
 .  
4) Create   
  by randomly removing one subject from   
  and randomly adding one 
subject from   
 .  
5) Calculate  
 
based on   
 .  
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6) If  
 
   
 
, sample   
  is replaced by sample   
  as the new “best” sample. Else, 
sample   
  is replaced by sample   
  with probability = exp{  
 
  
 
    }.That is, 
always accept a favorable move and sometimes choose the less favorable move with 
decreasing probability as the system cools.  
7) Define         . 
8) Continue steps 8-10 iteratively until step 11 is satisfied, create sample   
    from 
sample   
  in a similar fashion, and calculate  
   
 and  
 
 based on   
    and   
 , 
respectively. 
9) If  
   
   
 
, sample   
  is replaced by sample   
    as the new “best” sample. Else, 
sample   
  is replaced by sample   
    with probability = exp{  
   
  
 
    }. 
10)            
11) Stop when       
 
The final sample of    at the last iteration is then selected as the optimal sample to be 
phenotyped in Stage 2.  
           The algorithm is programmed in R (version 2.11.0; www.r-project.org). The parameters 
used for the runs of the SA algorithm described herein were as follows:   =400,  =0.9999, 
 =0.000001. The impacts of values assigned to these parameters were explored during the course 
of the study. 
 
Data simulations  
Two-stage approach using genotyped data 
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      We assumed a normally distributed trait with mean 0 and variance 1 that is associated, in an 
additive fashion, with an “index” marker (a SNP scored 0, 1 or 2 for number of copies of the 
minor allele). We considered a range of allele frequencies [see below] for the index marker. For 
each simulation condition, we assigned a minor allele frequency (MAF) for the index marker and 
a corresponding effect size β for the index marker given its’ MAF based on our assumption that 
the proportion of total variation explained by the associated index marker with respect to MAF is 
constant. We assumed that the MAFs for the remaining (    ) non-index markers (important 
for Stage 2) follow a uniform distribution within the range from 0.05 to 0.5 and that these 
markers are not associated with the trait. Genotype data for each genotyped marker was 
simulated using the binomial distribution given their corresponding MAF assuming marker 
genotypes follow Hardy-Weinberg equilibrium. The phenotype data were simulated, using 
random draws from a normal distribution, conditional on the genotype at the index marker and 
its corresponding β.  Statistical tests of significance (testing H0: β = 0 vs HA: β ≠ 0) were 
performed using t-tests implemented in R. 
        We performed 500 simulations for each model we tested. For each simulation, we first 
simulated the index marker data and trait, conditional on the index marker, on the    subjects 
phenotyped in Stage 1 and then assessed the significance of the index marker using a standard t-
test. If this p-value was less than          , we then we applied the SA-based approach to 
select    subjects to be phenotyped in Stage 2 from the remaining           subjects, so 
that  
∑ ∑          
   
   
  
   
  
 is maximized across the   Stage 2 selected markers; otherwise, we 
randomly selected    subjects to be phenotyped in Stage 2 from the remaining             
subjects (Stage 2 sample selection is assumed to be random with respect to the index marker if 
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that marker is not included in the SA optimization). Phenotypes were then simulated for the     
Stage 2 participants conditional on their genotype at the index marker. 
We considered two previously described alternative strategies for evaluating the 
significance of our two-stage findings (180), namely the “joint-analysis” and the “replication-
based analysis” approaches. For the joint-analysis approach, after selecting    Stage 2 subjects, 
the index marker genotype-phenotype data were combined across all subjects from Stages 1 and 
2 and we calculated the significance of the association between the trait and the index marker 
using the final sample of                 subjects. The overall power for the joint-
analysis design was defined by the proportion of simulations (out of 500) that achieve a p<5x10
-8 
(a standard GWAS significance threshold that is likely conservative in this setting of evaluating 
only directly genotyped markers). For the replication-based analysis design, power was defined 
as the proportion of simulations where 1) the index marker was selected for inclusion in Stage 2 
AND 2) the index marker achieved a p<0.05/   using only the    Stage 2 samples. Power for 
both approaches was compared to the power obtained from a single-stage study based on 
randomly selecting all       samples for phenotyping. To reduce random noise in the 
comparisons, for each simulation, the    samples in the joint-analysis, replication-based analysis 
and random sample approaches were the same    samples.  
        In order to investigate how the power of the two-stage designs depends on           
and          , and to determine good choices for           and           for index 
markers with different MAFs, we calculated the power for the different study designs using 
various combinations of parameters: MAFs [0.05, 0.1, 0.2, 0.4]             [0.00001, 
0.000025, 0.00005, 0.0001, 0.0002, 0.0005]             [0.375, 0.5, 0.625, 0.75, 0.875]. We 
assumed that                (combined # subjects phenotyped in Stage 1 and 2 / # number 
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of total subjects with genotype data) = 2,000/4,000 in all situations. We further assumed that the 
proportion of total variation explained by the associated index marker was independent of MAF 
and equal to a constant value of 2%. 
 
Two-stage approach using imputed genotype data 
             Genotype imputation is a widely used zero-genotyping-cost method that can increase 
both genomic coverage and power to detect genetic associations (181).  In addition to MAF and 
effect size, statistical power for an imputed index marker is also a function of the genotype 
imputation quality for the variant. Unlike standard power analyses for single variants, for our 
selective-phenotyping approach, the power for the index SNP is also a function of the MAF and 
imputation quality of the other m2-1 non-index Stage 2 selected markers, as these features will 
impact which samples are ultimately selected for phenotyping in Stage 2.  
             For the index marker, we calculated statistical power for the joint-analysis design (using 
significance criterion p<5x10
-8
), with different combinations of parameters: MAFs [0.05, 0.1, 0.2, 
0.4]             [0.625, 0.75, 0.875]   R2 [0.95, 0.80, 0.65, 0.50], and compared these results 
to what would be obtained using a random phenotype sample selection approach. We set the 
parameter           =0.00005 and, similar to the previous simulations for genotyped markers, 
assumed the true marker genotype explained 2% of the total trait variation. For the index marker, 
we generated probabilities                      of genotype AA, Aa, and aa, respectively, for each 
individual i using the Dirichlet distribution given the MAF and corresponding R
2
. We calculated 
allelic dosage for individual i at marker j as                  . For each subject, we 
randomly drew the true value of the index marker genotype, from the posterior probabilities for 
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the three possible genotypes (AA/Aa/aa), and simulated the phenotype data    using a normal 
distribution with the mean conditional on the assigned index marker genotype. 
           For all other markers included in the Stage 2 selection process, we did not assume values 
of MAF or R
2
 (imputation quality). Instead, we sampled these values from their approximate 
empirical distributions based on Hapmap Phase II imputed data from the Jackson Heart Study 
(JHS). We first made a histogram of the distribution of MAFs of HapMap Phase II imputed data 
from the JHS and fitted a high-ordered spline function (f) that reasonably fitted the observed 
distribution (Figure 5.2). We then sampled MAFs under f, using a Monte Carlo method, to 
obtain the MAFs for the non-index Stage 2 markers. To be specific, each time we drew a random 
number x from uniform distribution within the range from 0.005 to 0.5 (the range of MAF in 
JHS HapMap Phase II imputed data), and a random number y from the uniform distribution with 
bounds ranging from 0 to the maximum value that can be achieved by f. If the point (x,y) was 
above the spline of f, we rejected the marker; if the point (x,y) was under the spline, we accepted 
the marker in our sample.  
               Imputation quality varies as a function of MAF, with less common markers having 
poorer imputation quality on average than more common markers. We noted that the distribution 
of R
2
 appeared to follow a      distribution for markers within a given MAF range. To estimate 
this conditional      distribution, we estimated the mean (   and variance (   of the imputation 
quality R
2 
for a given MAF. To accomplish this, we created a fine grid of consecutive MAF bins 
and for each bin we obtained the mean and variance of R
2
 values within the bin. We then fitted 
higher-ordered splines to create functions of the mean and variance for a given MAF. We 
assumed, within each MAF bin, that R
2
 follows a      distribution with parameters a and b, and 
thus,       
 
   
 and       =
  
             
. By inverting the dependent and independent 
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variables in these two functions we solve for the parameters      
   
 
 
 
 
  and     
 
 
 
     
   
 
 
 
 
  for the corresponding Beta function. For a given selected marker we then 
randomly generated a R
2 
from the      distribution Beta (a,b) conditional on the marker’s MAF. 
To assess the overall fit of our      model, we overlayed the curve generated by the density 
function of the      distribution Beta (a,b) on the corresponding empirical density of R2 values 
(histograms) for a range of MAF bins (Figure 5.1). Based on these results, it appeared our model 
was reasonable 
………We then performed the Stage 2 SA sample selection model on allelic dosage     for the 
   Stage 2 markers to select the subset of subjects which maximizes the value of 
∑ ∑          
   
   
  
   
  
  The association p-value for the index marker j* was calculated by regressing 
the simulated phenotype    on the allelic dosage     .  
 
Example:  C-Reactive Protein (CRP) in the Jackson Heart Study (JHS) 
          We evaluated the performance of our two-stage selective-phenotyping approach in a study 
with real data. JHS is a longitudinal, population-based cohort study that aims to investigate 
cardiovascular disease risk factors in African Americans from Jackson, Mississippi(113). The 
design, recruitment and initial characterization of this study was described in detail 
elsewhere(114). We first performed a GWAS on a total of 2987 JHS subjects with available CRP 
phenotype data and genome-wide genotype data imputed based on 1000 Genome Project panel. 
The levels of CRP were naturally log-transformed to approximate normality of residuals after 
accounting for age, sex and BMI. Extreme values of CRP (>100) were removed as the extreme 
values suggested acute infection in those subjects. Thirty-eight million markers were imputed, 
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using MACH 2.0 (118), based on a reference panel consisting of the complete sample of the 
1000 Genome Project participants (Nov 2010, Version 3); only markers with MAF > 0.05 and 
estimated imputation quality of R
2
 > 0.3 were included in further analyses. The association 
between CRP and imputed markers were tested using multivariable linear regression models in 
MACH2QTL v.1.08 (118), adjusting for age, sex, BMI, smoking status (yes/no), and the first 10 
principal components generated from EIGENSOFT (120). An additive mode-of-inheritance 
model was assumed for genotype;  coefficients, representing the estimated change in 
transformed trait value associated with each additional copy of the effect allele, and the 
corresponding standard errors were reported. 
        We next considered the scenario where we could only afford to measure CRP in 1500 JHS 
subjects in total. Based on the results of simulated data, we used the parameters setting as 
          =0.75 and           =0.000025. Specifically, we first randomly selected 1125 
(=1500 0.75) subjects in stage 1 and performed a GWAS on this subset of subjects. Due to the 
high coverage of 1000 Genome Project panel and linkage disequilibrium (LD) structure among 
markers, we selected only the top marker from each of the top 25 loci instead of the top 25 
individual markers (i.e. we selected only one SNP at each locus, based on physical location, so 
that the final selected 25 markers were not likely to be in high LD with each other),identified in 
Stage 1, to be followed up and included in SA phenotype-selection process in Stage 2. In Stage 2, 
we identified the 375 subjects, from the remaining 1862 (=2987-1125) JHS subjects available for 
phenotyping, that maximized the average genotypic dispersion across these 25 selected markers. 
Next, we combined the imputed genotype and phenotype data from the 1125 subjects in Stage 1 
and the 375 subjects selected in Stage 2 to assess whether there was evidence of association for 
the same loci found at p<5x10
-8
 in the complete JHS sample. In comparison, we used the same 
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1125 subjects in Stage 1 combined with 375 randomly selected JHS subjects from Stage 2 and 
made the same assessments. We performed 100 different trials, each using a different random 
Stage 1 sample, and calculated the number of times each established GWAS signal reached a p-
value of 5x10
-8
, 5x10
-7
, and 5x10
-6 
using either of the two approaches.  
 
Results 
Two-stage design using directly genotyped markers 
  Our results showed we can get modestly increased power using a two-stage joint-analysis 
selective-phenotyping study over studies based on a random selection of subjects. In general, 
estimated power was greatest when including large samples in Stage 1 (                ) 
combined with higher selectivity of markers (lower          ) for inclusion in the Stage 2 SA 
phenotype-selection algorithm, where the relative increase in power approached 10% compared 
to using unselected samples. Power comparisons between our two-stage selective-phenotyping 
approach, using joint analyses, and the conventional single-stage random sample approach are 
shown in Figure 5.3 and Figure 5.4 across alternative values of           and          , 
respectively. The relationship between the relative increase in overall power [(overall power 
achieved by SA - overall power achieved by random selection)/overall power achieved by 
random selection] and           across different choices of index marker MAF and 
          are shown in Figure 5.5. In most scenarios, the maximum benefit in power gained 
by our two-stage joint-analysis approach over random selection was achieved using higher 
values of            0.75, 0.875). In most scenarios, the minimum benefit was achieved for 
markers with higher MAF (0.4). We also investigated the relationship between the relative 
increase in power and           for different scenarios of the index marker MAF and 
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          (Figure 5.6). No obvious pattern between relative increase in power and 
          was observed for lower           values, but a strong trend was observed when 
          was as high as 0.875 (a lesser trend was observed for           = 0.75) for lower 
power being associated with increasing values of          .  The power achieved by the two-
stage replication-based study design was considerably worse than both random sample selection 
and the two-stage joint-analysis design (data not shown), despite the phenotypic sample 
enrichment in Stage 2. Thus, we dropped the two-stage replication study design from further 
consideration. 
 
Two-stage replication study using imputed genotype data 
 Our results using imputed genotype data were consistent with the results from the directly 
genotyped results, showing we can achieve increased power using the two-stage joint-analysis 
study over studies based on random selection of subjects. Not surprisingly, the relative power of 
an imputed index marker is markedly lower than when using a directly genotyped index marker 
when the index marker has low imputation quality. However, the relative gains or our proposed 
approach compared to using randomly phenotyped samples still exists even for poorly imputed 
index markers. The overall power depending on           is shown in Figure 5.7. No obvious 
pattern between relative increase in power and           or MAF was observed, suggesting 
that our approach is not overly sensitive to parameter choices and that its performance using 
imputed data is robust across a wide range of alternative scenarios. 
C-Reactive Protein (CRP) in the Jackson Heart Study (JHS) 
The top markers that reached genome-wide significance in a total of 2987 JHS subjects 
are listed in Table 5.1.  Among the five signals, three of them (CRP, APOE, and HNF1A) were 
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established GWAS signals, and thus we tested how many times (out of 100 random trials) each 
of the three established GWAS signal reached a P value of 5x10
-8
, 5x10
-7
, 5x10
-6
, 5x10
-5
, and 
5x10
-4
 using our two-stage selective-phenotyping approach and a random phenotyping selection 
approach (Table 5.2) that included a total of n=1500 JHS participants. The CRP locus signal was 
detected at a genome-wide significance level (P<5x10
-8
) in all 100 trials using both approaches. 
The APOE signal was detected at genome-wide significance level in 29 out of 100 trials using 
the selective-phenotyping approach and only 10 times using the random selection approach. The 
HNF1A signal was detected using a genome-wide significance threshold only once using both 
approaches, and the performance of both approaches were similar when using less stringent 
significance levels.  
Discussion  
        Two-stage genetic association studies have played an important role in reducing the cost 
and increasing the power of genetic association studies. Historically, two-stage designs have 
involved genotyping a subset of phenotyped subjects (in Stage 1) on 100,000’s of markers 
contained on a large-scale genotyping array and then performing targeted genotyping on the 
remaining phenotyped subjects (in Stage 2) on a subset of the markers that demonstrated the 
greatest evidence for association in the Stage 1 participants.  Here, we proposed an alternative 
two-stage genetic association study design, where it is assumed that we have an unmeasured 
quantitative trait of interest but that all subjects have available directly measured or imputed 
genome-wide genotype data. We described a selective-phenotyping method that uses SA to 
identify the optimal subset of subjects to be phenotyped in Stage 2 of a two-stage GWAS based 
on their available directly genotyped and/or imputed dosage data across markers that had the 
strongest evidence for association in a subset of randomly selected, newly phenotyped, Stage 1 
 119 
 
participants. The method is particularly designed for the scenario where cost, or other, 
constraints prohibit the phenotyping of the entire cohort of participants that have available 
genetic data. Through both simulations and a real example, we show that our two-stage selective-
phenotyping approach can increase the power to identify significant associations between newly 
measured quantitative-trait phenotypes and either directly or imputed genotyped markers 
compared to studies that randomly select subjects for phenotyping.  
             We proposed to use a computationally efficient method based on SA to find the maximal 
genotypic dissimilarity across multiple selected markers of interest, rather than simpler methods 
that only consider a single marker at a time. In comparison with other optimization algorithms, 
SA does not require calculation of derivatives and subsequent root finding, which can be 
intractable in many complicated settings. The SA optimization algorithm, as described, does not 
make any assumptions regarding Hardy-Weinberg equilibrium or marker independence and is 
remarkably flexible. While not described herein, weights can be readily included for certain 
markers, if desired, to increase the influence of these markers on sample selection. Along these 
lines, our two-stage approach could include prior information (e.g. force including a previously 
reported associated marker in the optimization scheme regardless of Stage 1 results) to influence 
phenotype selection in the remaining samples. We recommend considering LD pruning top 
markers prior to marker selection for Stage 2, as failure to do so will result in some regions 
having disproportionate influence on the phenotype selection procedure. An investigator might 
also choose to optimize alternative functions depending on their underlying hypothesis. For 
example, if an investigator wants to assume a rare-recessive mode-of-inheritance model then 
genotype could be rescored 0 (non-carrier) or 1 (carrier of at least on risk allele), rather than our 
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described values of 0, 1 and 2 based on assuming an additive inheritance model, prior to 
conducting the SA optimization. 
             We attempted to identify reasonable parameter choices for selecting samples, chosen 
from a larger cohort, for phenotyping (for both Stage 1 and Stage 2 samples) to provide greater 
power than a simple random sample selection for phenotyping.  The balance is between selecting 
a high enough proportion of subjects in Stage 1, so that the truly associated markers rise to the 
top of the results (so they can be included in sample selection in Stage 2), while leaving enough 
remaining subjects for phenotyping in Stage 2, where we can see some benefit of performing 
selective phenotyping for these markers. Interestingly, our approach was not overly sensitive to 
parameter choices and remained robust across a wide range of MAFs,          , and 
         . In general, though some benefit of increased power was observed across most 
combinations of          , and          , it appears that using a larger sample selection in 
Stage1 and a stricter marker inclusion in Stage 2 provides the best results. 
 Unlike more traditional two-stage genotyping designs, all markers analyzed initially in 
Stage1 will also be evaluated in the completed Stage 1 + Stage 2 samples when using our two-
stage selective-phenotyping approach. All Stage 1 + Stage 2 samples will have measured 
genotype and phenotype data available for analyses. For the markers not included in the Stage 2 
optimization procedure, there would be little expected impact on their respective parameter 
estimates or estimated power estimates compared to what would typically be obtained from 
using random sample phenotype selection for the remaining Stage 2 samples, assuming that these 
markers are reasonably independent of those markers included in the Stage 2 optimization. 
  The clear advantage of our approach is the increased power to detect novel associations 
compared to a random sampling design under the same fixed sample size constraint. It is 
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important to note that our sample procedure does not directly cause the effect (β) estimates to be 
biased. Unlike the extremes-of-phenotype selective-genotyping study design, our procedure does 
not inherently change the trajectory of the effect estimate under the alternative hypothesis, rather, 
our increase in power is obtained by increasing the precision (shrinking the variance) of the 
index marker effect estimator. However, the effect estimates of the best marker results (including 
many of the markers which would likely be used in the Stage 2 phenotype selection) using our 
approach would typically be inflated, per the winner’s curse phenomenon, just like they would 
be for any other large-scale discovery study, including studies that use random sample phenotype 
selection.  Finally, while we describe our approach for measuring a new quantitative trait, we 
note that the general two-stage selective phenotyping approach should also be considered when 
measuring new dichotomous traits, where the probabilities of the different outcomes are a 
function, under the alternative hypothesis, of the marker genotypes (e.g.. we would expect to 
increase the proportion of cases by selectively genotyping uncommon homozygotes for an index 
marker). 
          There are also some possible limitations in the proposed two-stage study design that 
warrant consideration. First, our two-stage phenotyping design requires additional time to 
phenotype samples (phenotyping is performed in two batches, with the second batch conditional 
on the association results from the first batch). Investigators will have to decide if time 
constraints are an important factor and if additional phenotyping costs occur due to the piecemeal 
approach. Second, phenotyping subjects in each stage under different situations may induce 
batch effects in the measures of phenotypes. Such batch effects could be remedied by the simple 
inclusion of an additional covariate for batch in the regression models or use of meta-analysis.  
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Table 5.1 Top markers that reached genome-wide significance (p<5x10
-8
) in 2987 subjects 
 
Chr # of Markers Most significant SNP Pos(hg19) EA EAF RSQR N β SE P Function Gene 
1 111 rs73024710 159689965 T 0.17 0.99 2978 0.44 0.04 1.19E-30 intergenic APCS-CRP-DUSP23 
19 10 rs10119 45406673 A 0.25 0.56 2978 -0.33 0.05 2.98E-13 UTR3 TOMM40-APOE 
7 1 rs12698712 68106789 G 0.10 1.00 2978 -0.27 0.05 2.30E-08 intergenic STAG3L4-AUTS2 
12 1 rs11047572 24836927 A 0.26 0.88 2978 0.19 0.04 3.38E-08 intergenic LINC00477-BCAT1 
12 1 rs1169284 121419926 C 0.25 0.90 2978 -0.19 0.04 3.61E-08 intronic HNF1A 
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Table 5.2 Times each of the 3 established GWAS signal (CRP, APOE, and HNF1A) reached 
a P value of 5x10
-8
, 5x10
-7
, 5x10
-6
, 5x10
-5
, and 5x10
-4
 using either approach (SA/random) 
 
Chr Gene SNP # P<5x10
-8
 # P<5x10
-7
  # P<5x10
-6
 # P<5x10
-5
 # P<5x10
-4
 
1 APCS-CRP-DUSP23 rs726640 100/100 100/100 100/100 100/100 100/100 
19 TOMM40-APOE rs1160985 29/10 44/34 65/60 90/90 100/100 
12 HNF1A rs1169284 1/1 8/4 16/16 41/42 74/69 
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Figure 5.1: Histograms of R
2
 across the spectrum of MAF bins and the curve generated by 
density function of Beta distribution 
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Figure 5.2: Histogram of MAF of HapMap Phase II imputed data from the Jackson Heart 
Study 
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(a) 
 
(b) 
 
(c) 
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(d) 
 
(e) 
 
(f)  
Figure 5.3 Power of a two-stage GWAS with a subset of subjects randomly selected or 
selected based on SA to be phenotyped in Stage 2 depending on          . n.pheno=2000, 
n .geno=4000 a) pi.marker=0.000001. b) pi.marker=0.000025. c) pi.marker=0.00005. d) 
pi.marker=0.0001. e) pi.marker=0.0002. f) pi.marker=0.0005 
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(a) 
 
(b) 
 
(c) 
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(d) 
 
(e) 
Figure 5.4 Power of a two-stage GWAS with a subset of subjects randomly selected or 
selected based on SA to be phenotyped in Stage 2 depending on          . n.pheno=2000, 
n .geno=4000 a) pi.sample=0.375; b) pi.sample=0.5; c) pi.sample = 0.625; d) pi.sample = 0.75; e) 
pi.sample = 0.875 
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Figure 5.5 The relationship between relative power and           for different MAF. 
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Figure 5.6 The relationship between relative power and           for different MAF. 
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(a) 
 
(b) 
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(c) 
 
(d) 
Figure 5.7 Power of a two-stage GWAS with a subset of subjects randomly selected or 
selected based on SA to be phenotyped in Stage 2 from a total sample of subjects with 
available imputed genotype. n.pheno=2000, n .geno=4000, pi.marker=0.000050 a) Imputation 
quality R
2
=0.95; b) R
2
=0.80; c) R
2
=0.65; d) R
2
=0.50.  
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CHAPTER VI: DISCUSSION 
 
         In the preceding chapters, I described a collection of findings that further our 
understanding of genetic architecture of two CVD related biomarkers in AAs who have a higher 
prevalence of CVD than other ethnic groups in the United States, and blood pressure measures in 
a Chinese population. I first conducted a genome-wide association study for iron-related 
phenotypes including serum iron, serum ferritin, SAT, and TIBC in 2347 AAs participating in 
the JHS. I observed a novel region on chromosome 3, GAB3-G6PD, significantly associated with 
ferritin levels and identified the putative causal variant in this region. I also observed multiple 
independent SNPs associated with TIBC in the TF region using conditional analyses. The two 
independent associations for TIBC at TF and the association for ferritin at GAB3 were 
successfully replicated in HANDLS. Next, I conducted a genome-wide admixture and 
association study, and an exome-wide association study using Human Exome Beadchip for Lp(a) 
in 2895 AAs in JHS. I observed significant (P<5x10
-8
) associations for hundreds of SNPs 
spanning an ~10Mb region on 6q surrounding the LPA gene. Interestingly, after adjusting for 
local ancestry, the region containing significantly associated SNPs became much narrower and 
was centered over the LPA gene (<1Mb). Gene-burden tests found significant associations 
between Lp(a) and aggregate collections of SNPs in LPA and APOE. Next, I tested the 
interaction between several environmental factors and four candidate genes in affecting blood 
pressure measures in 7319 Chinese in CHNS. I observed that the signal at rs1458038 in the 
FGF5 region exhibited a significant genotype-by-BMI interaction affecting blood pressure, with 
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the strongest variant effects in those with the highest BMI. This pattern of interaction was also 
observed in an independent sample of men from FAMHES. Finally, I described a selective 
phenotyping method that uses a simulated annealing (SA) algorithm to identify the optimal 
subset of subjects to be phenotyped in Stage 2 of a two-stage GWAS based on their available 
directly genotyped and/or imputed dosage data across multiple SNPs of interest, and showed that 
increased power could be achieved using this method. 
            Several aspects of this work are worth highlighting because they illustrated novel 
findings of genetic architecture of certain traits and shed some light on future directions. In 
Chapter II, we observed the estimated average (“global”) proportion of African ancestry was 
significantly associated with lower levels of TIBC, serum iron, and SAT, and nominally 
associated with higher level of serum ferritin - which are entirely consistent with previous 
findings reporting lower levels of TIBC, iron and SAT and higher level of ferritin, on average, in 
AAs compared to European Americans (96, 97). In Chapter III, I observed that a higher level of 
estimated global African ancestry was significantly associated with higher levels of Lp(a), which 
is also consistent with previous findings which reported that Lp(a) levels in populations of 
African ancestry are much higher (2~4-fold) than in populations of European ancestry (111). 
Interestingly, the observed higher global African ancestry associated with higher Lp(a) levels 
was entirely explained by higher African local ancestry surrounding the LPA gene. These results 
implicate novel genetic risk factors in AAs and underscore the importance of studying this 
population for genetic risk factors that uniquely/disproportionately impact them. The Jackson 
Heart Study (JHS) provides a unique opportunity to study the genetic basis of complex CVD 
related traits in AAs. The JHS is a longitudinal, community-based, observational study designed 
to identify risk factors for the development of CVD in more than 5000 AAs recruited from non-
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institutionalized adults from urban and rural areas around the Jackson, Mississippi, metropolitan 
area (85). Jackson has the largest percentage (36.3%) of AAs in the United States, with the 
overall CVD mortality in AA men and women 12% and 22% higher, respectively, than in the 
rest of the nation.  As the largest single-site, prospective, epidemiologic investigation of 
cardiovascular disease among AAs ever undertaken, JHS will continue show its value in 
exploring the reasons for this disparity of CVD prevalence between AAs and EA and lead to new 
approaches to reduce it. 
           Typically after establishing a GWA signal, an important follow-up analysis is to 
determine whether of additional independent signals exist in the associated region. The 
identification of multiple signals at individual loci could explain additional phenotypic variance 
(‘missing heritability’) of common traits, and help identify the causal genes or regulatory 
mechanisms.  In my work from Chapter II, I identified a second significant independently 
associated SNP in the TF region for TIBC. Our report was the first to identify such a second 
signal. Interestingly, this second signal (index SNP rs9872999 which maps to an intergenic 
region approximately 10Kb proximal to TF) only became significant at the genome-wide level 
after conditioning on our top TF region SNP rs8177253. The allele associated with an increase in 
TIBC for rs8177253 is preferentially on the same haplotype with the allele associated with a 
decrease in TIBC for our top variant rs9872999. Thus, the mean effects for rs9872999 are shrunk 
towards the null when not factoring in genotype for rs8177253. The presence of multiple 
association signals at individual loci is an indicator of allelic heterogeneity, which is defined as 
the presence of multiple alleles that act through one gene to influence a trait. A recent study 
investigating the patterns of association consistent with allelic heterogeneity using cis gene 
expression phenotypes observed several patterns of association when analyzing single SNPs 
 137 
 
compared with multiple SNPs at the same loci (182). The frequency with which trait raising 
alleles segregated on the same or opposite haplotypes affected the degree to which association 
statistics ‘fell’ or ‘jumped’ in multivariable compared with univariable analyses. If two trait 
raising alleles segregated on the same haplotype, the association statistics tend to ‘fall’ in 
multivariable analyses because multivariable analysis will adjust for the correlated effect of the 
other primary SNP on the secondary SNP. If two trait raising alleles segregate on the opposite 
haplotype (i.e. one trait associated raising allele and the other trait associated lowering allele 
segregate on the same haplotype), the association statistics tend to ‘jump’ because a 
multivariable analysis will adjust for the cancelling out effect of the other SNP. The distinction 
between two independent signals and one partially tagged signal is rather important when trying 
to use association results to identify causal genes, or when choosing SNPs for functional studies. 
        Another important follow-up analysis after establishing a GWA signal is to identify the 
actual causal variants and to determine the underlying functional mechanisms. Through a variety 
of approaches, my work identified both common and uncommon variants which are potentially 
causal to the variation of CVD related phenotypes. In Chapter II, I observed a functional 
missense variant in G6PD, rs1050828 (MAF=0.13, leading to a Val68Met amino acid 
substitution), which was associated with ferritin but narrowly missed genome-wide significance 
(p=9.1x10
-8
). This variant was imputed in the original GWAS data. The association between the 
top genome-wide significant variant, rs141555380, in this region and ferritin disappeared after 
adjustment for this functional variant (rs1050828) at G6PD (p = 0.55). This functional variant is 
implicated in malaria resistance, and the A- form of G6PD deficiency in Africa is under strong 
natural selection from the preferential protection it provides against life-threatening malaria 
(110). This is the first time G6PD-GAB3 region has been reported to be significantly associated 
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with ferritin, a specific iron-related measure in AA. In Chapter III, my work identified a splicing-
altering variant rs41272114 in the LPA gene, a nonsynonymous variant rs7412 in the APOE gene 
and a second independent nonsynonymous variant rs769455 in the APOE gene that were 
significantly associated with Lp(a) level using data from the Ilumina Human Exome Beadchip. 
Although exome- and whole-genome sequencing is becoming increasingly affordable, 
genotyping arrays still remain to be a cost-effective approach to investigate rare variants in the 
human genome. The goal of this Human Exome Beadchip array was to enable an intermediate 
experiment between current genotyping arrays, which focus on relatively common variants, and 
exome sequencing of very large numbers of samples, which focus on rare and low-frequency 
coding variants. The Exome BeadChip contains 247,870 variants discovered through exome 
sequencing in ~12,000 individuals that are mostly protein-altering (nonsynonymous coding, 
splice-site and stop gain or loss codons) (64). So far, it has enabled identification of several rare 
and functional variants associated with fasting glucose, insulin processing, and type 2 diabetes 
susceptibility (65) (66). My work suggested custom genotyping array like Exome BeadChip can 
provide new insights for previously genotyped cohorts and enable the identification of functional 
variants in future genetic association studies. By following up thousands of targeted SNPs with 
prior evidence of association with related traits, custom targeted genotyping arrays will continue 
making contributions to discovering biologically functional variants and understanding potential 
mechanisms of disease pathogenesis. 
            A hot topic of debate in the field of genetic association studies is the “missing heritability” 
not explained by GWAS. It is believed that human complex traits are influenced by the 
interaction among genetic and environmental factors, thus investigation of such interactions will 
help explain some of the missing heritability and provide better insight into pathway mechanisms 
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for complex diseases (67). In Chapter IV, I detected a significant interaction between rs1458038 
5’ of FGF5 gene at 4q21 and BMI in affecting blood pressure measures in a Chinese population. 
Specifically, the effect of the rs1458038 risk genotype is considerably stronger in subjects in the 
heaviest quartile of the BMI distribution. This study implicates that the risk genotype at 
rs1458038 is particularly important in Chinese individuals with higher BMI. Candidate gene 
studies, such as the work I presented, to investigate hypothesized gene-environment interactions 
are quite common in human genetic research. With the development of large-scale high-
throughput genotyping technologies, genome-wide association gene-gene interaction (GWAI) 
and genome-wide environmental interaction (GWEI) studies are beginning to emerge. GWAI 
studies have a number of challenges including high-dimensionality, computational complexity, 
the absence/presence of marginal effects, the high burden of multiple test correction, and genetic 
heterogeneity (183). Given the unavailability of sufficiently large sample sizes and the 
dramatically increased multiple testing burden, GWAI studies usually end with no statistically 
significant findings. Several statistical approaches have been proposed, including regression-
based approaches and model-free approaches such as machine learning and pattern recognition 
(184). In general, the advantages of regression-based approaches are the clear interpretation of 
the model and the parameters that relate genotypes to phenotype. However, they have huge 
computational burden for testing higher-order interactions. In comparison, machine learning 
approaches are an alternative strategy to detect high-dimensional non-linear interactions. These 
latter approaches generally do not estimate parameters, but rather they find combinations of 
SNPs that can best separate cases and controls by epistatic interactions or joint effects. Some 
model-free approaches collapse high dimensional data into two dimensions; some try to detect 
differentially inherited SNP modules by hierarchically clustering SNPs that could be 
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interactively associated with a disease; and some use a multi-locus Mann–Whitney statistic to 
evaluate the joint association of a SNP combination. All these machine-learning approaches do 
not have the problem of an increasing number of parameters when modeling high-order 
interactions, but it is often difficult to interpret how the detected SNP combinations affect a 
disease. Despite the abundance of statistical methods and tools for interaction analysis in recent 
years, only a few of them have demonstrated replicable results and there is a need for further 
development and extension of these methods to identify gene-gene and gene-environment 
interactions in the context of genome-wide association studies.  
          Another novel and interesting finding is the importance of adjustment for local ancestry 
when performing the genetic association analysis in admixed populations. Admixed populations, 
those that descended from more than one ancestral population, offer a unique opportunity for 
mapping disease genes that have large allele frequency differences between ancestral populations. 
In Chapter III, I observed significant (P<5x10
-8
) associations for hundreds of SNPs spanning 
~10Mb region on 6q surrounding the LPA gene after adjusting for global ancestry estimate. 
Interestingly, after adjusting for local ancestry at 6q25.3, the region containing significantly 
associated SNPs got much narrower (from 9.8Mb to 0.7Mb) and was centered on the three genes 
SLC22A, LPL2 and LPA. This result suggests confounding between local ancestry and SNPs 
spanning the larger 6q region identified to be associated with Lp(a). Given the relatively recent 
admixture in the AA population, local ancestry can confound associations across a relatively 
large region surrounding the population-specific, or population-enriched, causal variant(s) (132, 
133). The observation that the associations in and near LPA remains robust after adjustment for 
local ancestry at LPA while the evidence for association further away dramatically declines 
suggests that the ancestry-specific (or highly-enriched) causal risk variant(s) resides in or near 
 141 
 
LPA and that most, if not all, of the observed associations outside this narrower region are 
spurious associations. My work suggested that formal genetic admixture analyses may point to 
the correct region containing the causal SNPs, but the region may not be precise enough for 
following up causal SNPs or even causal genes. In comparison, the local ancestry adjustment did 
control the background signals induced by association with local ancestry and effectively 
prevented false positive findings, which makes it a useful tool for fine mapping of regions 
identified from admixture mapping studies. Several association tests that adjust for local ancestry 
have been proposed. For example, one test is based on a conditional likelihood framework which 
models the distribution of the test SNP given disease status and flanking marker genotypes. This 
conditional likelihood makes it possible to explicitly model local ancestry differences among 
study subjects and thus it can eliminate the effect of population stratification at the test SNP. It is 
particularly useful when the directions of association are different in the ancestral populations. 
Another test, which is computationally simpler, is based on logistic regression, with adjustment 
for local ancestry proportion.  These association tests directly evaluate the correlation between a 
phenotype and a SNP genotype, and they directly compare the allele frequencies between cases 
and controls. In comparison, admixture mapping has substantially lower resolution than direct 
SNP association tests, as it does not make full use of the actual genotypes at each SNP and SNPs 
falling within the same extended ancestry block (which will be considerable larger than 
conventionally defined LD blocks due to the recent admixture events) will share similar 
admixture mapping signal. Future studies on association tests which can appropriately control for 
local ancestry is still needed as a general tool for genetic association studies in admixed 
populations.  
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             In addition to the application of genetic association studies for discovering risk factors 
for CVD related traits, my work also included investigation of the study design used to perform 
future genetic association studies. In Chapter V, I proposed a two-stage genetic association study 
design, where it is assumed that all subjects have available directly measured or imputed 
genome-wide genotype data but an unmeasured quantitative trait of interest. It is further assumed 
that cost constraints will limit the ability to measure the new phenotype on only a subset of study 
participants. I described a selective phenotyping method that uses simulated annealing (SA) to 
identify the optimal subset of subjects to be phenotyped in Stage 2 of a two-stage GWAS based 
on the identification of the most interesting SNPs from a GWAS study on a subset of unselected 
participants in Stage 1. Through both simulations and a real example, I showed that our SA 
algorithm-based two-stage approach achieves increased overall statistical power compared to a 
single stage study using a random selection approach for studies that have existing imputed or 
directly genotyped markers. While two-stage approaches are not novel for genetic association 
studies, the proposed two-stage phenotyping design is, to our knowledge, completely new. My 
study not only applied the SA-based two-stage phenotype selection approach to directly 
genotyped data, but to imputed dosage data as well. Since genotype imputation is widely used in 
GWAS, the extension of our approach to include these data is an important contribution to this 
two-stage study design. This approach was not sensitive to parameter choices and remained 
robust for a wide range of MAFs, proportional of markers to be followed up in Stage 2, and 
proportion of samples to be phenotyped in Stage 1. It is important to note that β estimates are 
unbiased by this procedure (other than winner’s curse which effects all large-scale discovery 
study designs, including random sample selection).  In fact, because our sampling design reduces 
variance of the estimates for the β’s, the estimates are actually more precise, on average, than 
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estimates based on random samples. The method would clearly benefit power and precision of 
estimated effects for markers included in the SA optimization in Stage 2, and it is important to 
note that there would be little impact on the parameter estimates or power for markers not 
included in the Stage 2 SA sample optimization versus what can be achieved from random 
sample selection, assuming that most non-included markers are independent of those used for 
optimization. 
               In general, the future of genetic studies of complex diseases will rely on a variety of 
statistical and biological approaches, including candidate gene studies, high-throughput high-
dimensional genotyping arrays, custom genotyping arrays targeting certain trait clusters (e.g. the 
Immunochip, the HumanCVD, MetaboChip), genome-wide gene-gene and gene-environment 
interaction analyses based on machine learning, whole-exome sequencing (WES) and whole-
genome sequencing (WGS), and replication of biological changes in animal models. In particular, 
as a result of the development of next-generation sequencing (NGS) technologies, WES and 
WGS have become considerably faster and more affordable over the past 5 years (62). In 
contrast to the first-generation sequencing, which was expensive in both time and money 
consuming to sequence the diploid human genome, NGS can now be used to sequence the same 
human genome within a few weeks for as little as US $4,000-5,000 (185). The prices and 
experimental time continue to decline, as the costs today for WGS are approaching $1,000 per 
sample. Common NGS applications include DNA-seq, RNA-seq, ChIP-seq, and methyl-seq 
(186). DNA-seq is to discover whether genomic variations including single nucleotide variants 
(SNVs), small DNA insertions or deletions (indels), copy number variations (CNVs), or other 
structural variants (SVs), are associated with human diseases. RNA-seq that measures gene 
expression changes is to discover new transcripts including noncoding RNAs and detect 
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transcript splicing or gene fusion events. ChIP-seq is to discover genome-wide transcription 
factor binding sites and chromatin-associated modifications. Methyl-seq is to discover various 
types of DNA methylation such as 5-methylcytosine and 5-hydroxymethylcytosine at single 
nucleotide resolution. These above common NGS applications may be adopted as mainstream 
tools for human genomics and routine procedures as part of the clinical laboratory for disease 
treatment in near future. Today, many analyses integrate information from multiple different 
sequencing applications (e.g. to assess whether rare DNA variants are associated with gene 
expression). These types of analyses will become for common in the near future and our ability 
to integrate these different types of data will likely lead to many new exciting discoveries.  
In conclusion, as CVD is the number one killer in the United States, understanding the 
contributing genetic risk factors as well as their interactions with environment risk factors is of 
critical importance for the prevention and treatment of the disease. The results of genetic 
association studies conducted in my dissertation further our understanding of the genetic 
architecture of several biomarkers related to CVD, and the two-stage phenotyping design 
provides a more powerful way to perform future GWAS studies when the cost of phenotyping 
prohibits the inclusion of all available subjects. 
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